

CURRICULUM VITAE

Howard (Jack) West, MD

Vice President of Clinical Development

Summit Therapeutics

3213 W. Wheeler St., #405

Seattle, WA 98199

Tel: 206-898-4515

Fax: 206-203-8284

e-mail: JackWestMD@gmail.com

Date Prepared: October 16, 2023

I. EDUCATION

University	Princeton University, Princeton, NJ; AB (<i>summa cum laude</i>) in Psychology (Physiologic), 1990
Graduate School	Univ. of Cambridge, Cambridge, UK; MPhil in Experimental Biology, 1992
Medical School	Harvard Medical School, Boston, MA; MD (<i>magna cum laude</i>), 1996

II. POST GRADUATE EDUCATION AND TRAINING

Internship	Brigham & Women's Hospital (Internal Medicine), Boston, MA, 6/96 – 6/97
Residency	Brigham & Women's Hospital (Internal Medicine), Boston, MA, 6/97 – 6/98 (clinical investigator track)
Fellowship	Fred Hutchinson Cancer Research Center/Univ of Washington (Medical Oncology), Seattle, WA, 10/98 – 10/2002

CERTIFICATIONS

- ABIM Diplomate #195591, Internal Medicine, 2000 (lapsed)
- ABIM Diplomate #195591, Medical Oncology, 2002, renewed 2012 & 2022 (active)

MEDICAL LICENSURES

- Alaska, Lic. #187152, issued 2022 (active)
- California, Lic. #C55294, issued 2012 (active)
- Idaho, Lic. # MC-1565, issued 2022 (active)
- Nevada, Lic. #22183, issued 2022 (active)
- Texas, Lic. #P3097 (active)
- Washington, Lic. #34681, issued 1998 (active)
- Wyoming, Lic. #14543C, issued 2022 (active)
- Arizona, Lic. #46173, issued 2012 (inactive)
- Florida, Lic. #P3097, issued 2012 (inactive)
- Hawaii, Lic. #16554, issued 2012 (inactive)
- Illinois, Lic. #036130103, issued 2012 (inactive)
- Massachusetts, Lic. #156940 (inactive)
- Maine, Lic #TNM23746 (telemedicine, inactive)
- Pennsylvania, Lic. #MD445767 (inactive)
- Virginia, Lic. #0101251883 (inactive)

III. PROFESSIONAL EXPERIENCE, POSITIONS & EMPLOYMENT

6/98 – 9/98	New England Sinai Hospital & Rehabilitation Center; Stoughton, MA Moonlight/Provisional Internal Medicine Staff
6/98 – 9/98	Beverly Hospital; Beverly, MA Moonlight/Provisional Internal Medicine Staff
6/98 – 9/98	Deaconess Waltham Hospital; Waltham, MA, Moonlight/Provisional Internal Medicine Staff
9/00 – 8/01	Stevens Hospital (now Swedish Hospital, Edmonds); Edmonds, WA Moonlight/Provisional Internal Medicine Staff (Medical Oncology)
10/01 – 10/02	University of Washington, Seattle, WA Acting Instructor, Medical Oncology
12/02 – 3/19	Swedish Medical Center/Providence Health Care, Seattle, WA Medical Oncologist, Medical Director, Thoracic Oncology Program
3/19 – 10/19	City of Hope Comprehensive Cancer Center, Duarte, CA Executive Director, Employer Services
10/19 – 10/23	AccessHope, Los Angeles, CA Vice President of Network Strategy, Senior Medical Director
10/23 – present	Summit Therapeutics, Menlo Park, CA Vice President, Clinical Development

Academic Appointments

Instructor, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, 2/02 - 12/02

Associate Professor, City of Hope Comprehensive Cancer Center, Duarte, CA 3/19 - 10/23

Clinical Administrative Appointments

Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA, 2002

Chair, Outreach/Education/Telemedicine Workgroup, Providence System, Seattle, WA, 2016

Executive Director, Employer Services, City of Hope Comprehensive Cancer Center, 2019

Vice President of Network Strategy, Senior Medical Director, AccessHope, Los Angeles, CA, 2022

Other Professional Activities

Founder & President, Global Resource for Advancing Cancer Education (GRACE), 501c3 non-profit providing free, expert information on current & best treatments to cancer patients/caregivers, 2007 – present

JAMA Oncology Founding Web Editor, 2014 – present

UpToDate, author and lung cancer section co-editor, 2016 – present

Medscape Columnist (monthly) & ASCO/World Conference on Lung Cancer Correspondent, 2014 – present

Founder & Moderator, Lung Cancer Expert Summit, 2017, 2018, 2019, 2020, 2021, 2022

ASCO Publications Editorial Board

IV. NATIONAL HONORS, SCHOLARSHIPS AND AWARDS HONORS AND AWARDS

1989	Howard Crosby Warren Junior Prize in Psychology, Princeton University
1990	Howard Crosby Warren Senior Prize in Psychology, Princeton University
1990	Phi Beta Kappa Society, Princeton University (overall academic achievement)
1990	Sigma Xi Society, Princeton University (scientific achievement)
1990	Daniel M. Sachs '60 Scholarship, Princeton University, for “character, commitment, & intelligence”
1990	Fulbright Scholarship to UK for overseas research
1990	Overseas Research Grant, UK government support (graduate research grant)
1992	Albert Schweitzer Society Urban Fellowship (supporting urban community medical care projects)
1992	Hartford Society Scholarship in Gerontology (support for health care projects for elderly patients)
1993	Howard Hughes Medical Institute Student Fellowship (supporting year of clinical/translational research at Massachusetts General Hospital)
1994-96	Howard Hughes Medical Institute Continued Support Fellowship (additional funding for clinical training and research)

- 2001 Southwest Oncology Group Young Investigator Training Program (developed clinical trial, later executed, presented, and published)
- 2001 ASCO/AACR Workshop in Clinical Cancer Research, Vail, CO (further developed clinical trial, later executed, presented, and published)
- 2002 GSK National Medical Oncology Fellows' Forum, Oral Presentation of original research (finalist)
- 2002-04 Innovators in Lung Cancer, International Program training in leadership in thoracic oncology (yearly summit, annual program x 3 years)
- 2012 Swedish Physician Leadership Program, training for cultivating leadership skills among faculty
- 2022 Healio Clinical Innovation of Year (AccessHope), based on my published introduction/summary
- 2022 "Eddie" Award for best essay/criticism, Medscape column on Willful Medical Ignorance
- 2023 GlobalData top 10 oncology influencers for H1 2023

V. CLINICAL ACTIVITIES

- 6/98 – 9/98 New England Sinai Hospital & Rehabilitation Center; Stoughton, MA;
Beverly Hospital; Beverly, MA;
Deaconess Waltham Hospital; Waltham, MA
Moonlight/Provisional Internal Medicine Staff, covering admissions, urgent care for inpatients on overnight shift, generally 1-4 admissions/shift
- 9/00 – 8/01 Stevens Hospital (now Swedish Hospital, Edmonds); Edmonds, WA
Moonlight/Provisional Internal Medicine Staff (Medical Oncology), covering weekend rounding on inpatients, admissions, consults, and calls from outpatients; 4-15 inpatients, 1-3 admissions per weekend
- 12/02 – 3/19 Swedish Cancer Institute, Seattle, WA
Medical Oncologist; Medical Director, Thoracic Oncology Program
75% clinical care (approximately 3.5 days/week); 15-20 patients per day seen solo (no APC or fellow support), approx. 70% thoracic, 30% genitourinary cancers; Leadership of clinical and research programs in thoracic oncology, seeing >75% of thoracic oncology patients, including outpatient referrals and inpatient consults, needing clinical care at largest private oncology program in the Pacific Northwest. Available/on call for patients Monday through Friday; weekend call every 8-14 weekends, covering inpatient oncology service typically with 15-30 inpatients, along with covering hematology/oncology consults and outpatient calls
- 3/19 – 10/23 AccessHope, Los Angeles, CA
Senior Medical Director
Clinical oversight of remote consult service, coordination of growing network, editing of broad range of cases in rapidly growing consult program
- 3/19 – 10/23 City of Hope Comprehensive Cancer Center, Medical Oncology, Duarte, CA
Medical Oncologist, Associate Professor
Longitudinal thoracic oncology clinic seeing and directly managing patients with thoracic malignancies, telemedicine clinic, outside clinical support as needed

VI. SERVICE TO INSTITUTION

Administrative Service

Member, Patient Care Quality Review Committee, Swedish Medical Center, 2003 – 2008
 Member, Clinical Research Steering Committee, Swedish Medical Center, 2003 – present
 Co-Chair, Swedish Prostate Cancer Symposium Planning Committee, 2004
 Member, Institutional Review Board, Cancer Research and Biostatistics (CRAB), 2004 – 2013
 Member, Swedish Medical Cancer Physician Leadership Forum, 2013 – 2019
 Co-Chair, Swedish Lung Cancer Symposium Planning Committee, 2014
 Member, Swedish Personalized Medicine Research Program Scientific Committee, 2017 – 2019
 Member, Quality of Cancer Care Committee, 2017 – 2019

Executive Director, Employer Services, City of Hope Comprehensive Cancer Center, 3/19 – 5/22
 Senior Medical Director & Vice President of Network Strategy, AccessHope, 5/22 – present
 Telehealth Pilot Program, 3/20 – present
 City of Hope Vaping/Smoking Cessation Task Force, 3/20 – present
 Lunch and Learn Committee, AccessHope, 1/2023 – present

Teaching Service

- Rotation of University of Washington Medical Oncology Fellows through clinics, 2003-2011, primarily in “shadowing” role, changing on monthly basis
- Instructor in fellowship lecture series, City of Hope, 2020, 2021, 2022 (Stage I-III NSCLC)

Other Research Mentoring Activities/Committees

- Global Resource for Advancing Cancer Education (GRACE) Patient Education Ambassador training program on social media and patient education
 - 2019 - 2020 – mentoring Narjust Duma (Univ. of Wisconsin) & Arjun Gupta (Johns Hopkins)
 - 2020 – 2021 – mentoring Ivy Franco (Harvard Medical School), Medhavi Gupta (Roswell Park Cancer Center), Ana Velazquez-Mañana (University of California-San Francisco), and Abdul Rafah Naqash (National Cancer Institute)
 - 2021-2022 – mentoring Aakash Desai (Mayo Clinic), Daniel Kwon (University of California San Francisco), Eric Singhi (MD Anderson Cancer Center), Edina Wang (Georgetown Lombardi Cancer Center)
 - 2022-2023 – mentoring Fernando Diaz (University of North Carolina, Chapel Hill), Ashish Gupta (Roswell Park), Sridevi Rajeeve (Icahn School of Medicine, Mt. Sinai), Mazie Tseng (University of California, San Francisco)
 - 2023-2024 – mentoring Jacob Adashek (Johns Hopkins Cancer Center), Karan Jatwani (Roswell Park Cancer Center), Matthew Kurian (Seidman Cancer Center), Kaitlyn Kyi (Wilmot Cancer Center), Meera Raghavan (University of California, San Francisco), Ivy Riano (Dartmouth Cancer Center), Dr. Gladys Rodriguez (Stanford Cancer Center)
- ABOUND Trials Steering Committee, 2015-2018
- RADIANCE Trial Steering Committee, 2017-2018
- IMpower All-Comers First Line NSCLC Trials Steering Committee, 2017 – present
- Expert panel for fellows and junior faculty, IASLC Targeted Therapies in Lung Cancer, Santa Monica, CA, 2/20.
- IASLC Academy Mentorship Program 2022, 2023: Mentoring a cohort of global thoracic oncology mentees
- ASCO Mentorship Program, 2023

VII. SERVICE TO PROFESSION

Professional Organizations

National/International	ASCO Scientific Committee, Lung Cancer Track, 2006-2008 and 2011-2014 Chair, ASCO Metastatic Non-Small Cell Lung Cancer Committee, 2013 NIH Thoracic Malignancies Steering Committee, 2013 – 2016 International Association for the Study of Lung Cancer, Educational/Conference Planning Committee, 2015, 2018 ACCC ALK-Positive NSCLC Advisory Committee, 2016 – present
Regional/Local	Washington State Medical Oncology Society, Board of Directors, 2006 – 2008

Government Activities N/A

NIH Study Section N/A

Editorships	Web Editor, JAMA Oncology, 2014 – present Section Editor, Lung Cancer, UpToDate
Editorial Boards	Journal of Clinical Oncology, 2012 – 2015 Oncology Business Review (OBR), 2013 – present Clinical Lung Cancer, 2013 – present Oncology Live, 2013 – present www.cancer.net (ASCO patient education), editorial board, 2014 – present
Journal Reviews	Cancer, Cancers, Cancer Investigation, Cancer Letters, Cancer Treatment Reviews, Clinical Cancer Research, Clinical Lung Cancer, Community Oncology, Digital Health, ESMO Open, Expert Opinion in Biological Therapy, Frontiers in Oncology, JAMA Oncology, JAMA Network Open, JCO Oncology Practice, Journal of Clinical Oncology, Journal of Telemedicine and Telecare, Journal of Thoracic Oncology, Lancet, Lancet Oncology, Nature Clinical Practice Oncology, Nature Reviews, Oncologist, Oncology, Target, Targeted Oncology, Targeted Therapies
Grant Reviews	Free to Breathe (lung cancer nonprofit), Lung Cancer Research Grant Review Committee, 2016
Community Service	Speaker, Lung Cancer Connection Annual Meeting, 2011 #LCSM (Lung Cancer Social Media) online twitter chat founding moderator, continued moderation 2016-2018 Speaker, LUNG FORCE, American Lung Association, 2016 Speaker, LUNGevity fundraiser, 2016-2018 Speaker, LUNGevity Patient HOPE Summit, 2017 International Association for the Study of Lung Cancer, Patient Advocacy Committee, 2011 – 2012, 2016 – 2017 Speaker, Bonnie J. Addario Lung Cancer Foundation Living Room, 4/2018 Section Chair, BinayTara Foundation Symposium on Cancer Care Disparities, 2022 Speaker/Chair, BinayTara Foundation Lung Cancer Symposium, 2021-2022
Other:	President, Global Resource for Advancing Cancer Education, cancer education non-profit providing free expert commentary for patients and caregivers Author, UpToDate, Non-Surgical Management of Early Stage NSCLC, Systemic Therapy for Early Stage NSCLC, Management of Oligometastatic NSCLC, Immunotherapy in Advanced NSCLC, Toxicity Management for Immunotherapy, Management of Brain Metastases in NSCLC, Management of Pericardial Effusions
Symposia	Bronchioloalveolar carcinoma (BAC): EGFR-based therapy and beyond; Winter Lung Cancer Conference, Miami, FL, 3/05 Bronchioloalveolar carcinoma (BAC): Predictive factors of response to EGFR TK inhibitors. Atlanta Lung Cancer Symposium, Atlanta, GA, 2005 Options for stage IIIA N2 NSCLC: Surgical and non—surgical options. Challenging Cases in Lung Cancer. Miami, FL, 7/07 Designs for targeted therapy trials: New problems, new potential, and new paradigms. IASLC Clinical Trials and Biostatistics Workshop, World Conference on Lung Cancer, Seoul, Korea, 9/07

Unresectable locally advanced NSCLC: Improving survival with old and new tools.
 Challenging Cases in Emerging Data, Chicago, IL, 9/07
 Advanced NSCLC: New targets and new tools. Challenging Cases in Emerging Data,
 San Francisco, CA, 9/07
 Recent developments in managing advanced NSCLC. Challenging Cases in Emerging
 Data, Scottsdale, AZ, 9/08
 Adjuvant chemotherapy for resected non-small cell lung cancer. Challenging cases in
 breast and lung cancer. San Diego, CA, 3/10
 Molecular markers and testing strategies in advanced non-small cell lung cancer,
 Challenging Cases in Breast and Lung Cancer, Orlando, FL, 5/10
 Adjuvant chemotherapy for resected non-small cell lung cancer. Challenging cases in
 breast and lung cancer. Las Vegas, NV, 9/10
 Molecular markers and testing strategies in advanced non-small cell lung cancer,
 Challenging Cases in Breast and Lung Cancer, Las Vegas, NV, 4/12
 Improving resistance to EGFR inhibition: The cornerstone remains targeted therapy.
 Great Debates & Updates in Thoracic Malignancies, San Francisco, CA, 5/12
 Optimal first line therapy for advanced NSCLC patients with an EGFR mutation,
 Challenging Cases in Oncology, Chicago, IL, 8/12
 Transitioning survival from months to years in advanced non-small cell lung cancer
 (NSCLC), Annual Oncology Symposium: Thoracic Malignancies, Seattle, WA,
 5/2014
 The third party in the exam room: Dr. Google and online patient communities:
 Annual Oncology Symposium: Thoracic Malignancies, Seattle, WA, 5/2014
 Nectin-4 antibody should not be standard of care treatment in advanced NSCLC despite a
 statistically significant improvement in OS. Personalized Therapies and Best Clinical
 Practices for Lung Cancer, Los Angeles, 10/14
 Immune checkpoint inhibitors in NSCLC: first line or second line? Personalized
 Therapies and Best Clinical Practices for Lung Cancer, Los Angeles, 10/14
 Social Media as a Tool for Physician and Patient Education. Pre-conference
 symposium, ASCO Annual Conference; Chicago, IL, 5/15
 First line treatment of choice for EGFR del 19 mutation-positive advanced NSCLC is
 afatinib. Great Debates & Updates in Thoracic Malignancies; La Jolla, CA, 7/15
 Next generation sequencing should be a part of the default workup for advanced
 NSCLC patients. Great Debates and Updates in Thoracic Malignancies; La Jolla,
 CA, 7/15
 Treatment options for EGFR T790M-negative acquired resistance. GRACE Targeted
 Therapies for Driver Mutations Patient Forum; San Francisco, CA, 10/15
 Broad molecular testing for advanced NSCLC; Personalized Medicine in Lung Cancer
 Conference, San Francisco, CA, 10/15
 Is the optimal therapy for advanced NSCLC with an activating mutation a
 combination?; Personalized Medicine in Lung Cancer Conference, San Francisco,
 CA, 10/15
 Treatment of EGFR T790M-positive acquired resistance in advanced NSCLC; EGFR
 Therapies in NSCLC 2.0 (ASCO CME symposium), Chicago, IL, 6/16
 Are there differences among first- and second-generation EGFR-directed therapies?
 Yes. EGFR Therapies in NSCLC 2.0 (ASCO CME symposium), Chicago, IL, 6/16
 Treatment of EGFR mutation-positive acquired resistance in advanced NSCLC:
 T790M-positive or T790M-negative; GRACE Targeted Therapies for Driver
 Mutations Patient Forum; Denver, CO, 8/16
 From evidence to everyday practice: Key influences on how oncologists treat patients;
 Business of Cancer, Dallas, TX, 10/16

Adding value for investigators and community-based oncologists: A changing world with new opportunities; Business of Cancer, Dallas, TX, 10/16

EGFR mutation-positive lung cancers: Choosing the best upfront treatment. New York Lung Cancer Symposium, New York, NY, 11/16

Best practices for managing advanced EGFR mutation-positive NSCLC after disease progression. Changing Treatment Paradigm After Progression in Advanced EGFR Mutation-Positive NSCLC (World Conference on Lung Cancer CME symposium); Vienna, Austria, 12/16

Selective immune checkpoint inhibitor therapy in patients with high PD-L1 expression; Immune Therapies for Cancer Master Class, Dallas, TX, 3/17

Evolving strategies for previously treated advanced NSCLC. Challenging Cases in Oncology, San Francisco, 5/17

Immune checkpoint inhibitors in first-line therapy for advanced NSCLC; Immune Checkpoint Inhibitors in NSCLC Care: Experts Address Clinical Challenges to Clarify Optimal Use (ASCO CME symposium), Chicago, IL, 6/17

Sequencing decisions for patients with ALK+ NSCLC beyond disease progression. ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs along the Disease Continuum (ASCO CME symposium), Chicago, IL 6/17

Treatment of EGFR mutation-positive acquired resistance in advanced NSCLC: Sifting through the wreckage: Assessing cancer information from sources of varying quality; GRACE Targeted Therapies for Driver Mutations Patient Forum; Cleveland, OH, 9/17

T790M-positive or T790M-negative; GRACE Targeted Therapies for Driver Mutations Patient Forum; Cleveland, OH, 9/17

For which NSCLC patients should immunotherapy be a lower priority?; Personalized Therapies in Lung Cancer Symposium; Los Angeles, CA, 10/2017

Treatment options for ALK+ NSCLC with acquired resistance to prior ALK inhibitor therapy: What now? Personalized therapies in lung cancer. Los Angeles, CA, 10/17

Proceed with caution: Immunotherapy in patients with prior immune-related adverse events on autoimmune disease; Personalized Therapies in Lung Cancer Symposium; Los Angeles, CA, 10/17

Treatment options for patients with ALK+ NSCLC that has progressed on a prior ALK inhibitor; Los Angeles, CA, 10/17

Selecting first line and second line therapy in the setting of EGFR mutation-positive NSCLC; HOPA Annual Conference, Denver, CO, 3/18

The evolving treatment landscape in locally advanced and metastatic NSCLC: Challenging Cases in Medical Oncology, San Diego, CA, 3/18

Immunotherapy for stage I-III lung cancer: Can we translate efficacy into more cures? Immune Checkpoint Blockade in NSCLC: Expert Perspectives on Current Standards and the Next Frontier (ASCO CME Symposium), Chicago, IL, 6/18

Immunotherapy for the treatment of lung cancer. SITC Advances in Cancer Immunotherapy Symposium. Seattle, WA, 11/18

Immunotherapy in first-line NSCLC. CME symposium, How Immunotherapy is Revolutionizing Lung Cancer Care. Canadian Lung Cancer Conference, Vancouver, BC, Canada, 2/19

Immune checkpoint inhibitor combinations as first line therapy for metastatic NSCLC, AACR CME symposium, Atlanta, GA 3/19

Current standards for stage III unresectable NSCLC. Evolution in the Care of NSCLC: Keeping Pace with Today's Best Practices (ASCO CME Symposium), Chicago, IL, 6/19

Current standards for patients with squamous NSCLC, low PD-L1. Evolution in the Care of NSCLC: Keeping Pace with Today's Best Practices (ASCO CME Symposium), Chicago, IL, 6/19

The why and who? Overview of immune checkpoint blockade in lung cancer. Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How? (AAFP CME Symposium). Phoenix, AZ, 9/19

TAK-788. Targeted Therapies in Lung Cancer IASLC Conference. Santa Monica, CA, 2/20.

EGFR TKI + antiangiogenic therapy as first-line therapy for patients with EGFR mutation-positive NSCLC. Targeted Therapies in Lung Cancer IASLC Conference. Santa Monica, CA, 2/20.

Weighing the evidence: interpreting molecular oncology data. Scripps Clinical Hematology & Oncology Conference 2020. La Jolla, CA, 2/20.

City of Hope Winter Department of Surgery Symposium. Social media and digital education comes of age. Monrovia, CA, 2/20.

Highlights in advanced non-small cell lung cancer. Virtual ASCO Direct Highlights. Phoenix, AZ, 7/20 (virtual).

Updates in Advanced NSCLC. International Conference on Advances in Hematology and Oncology 2020. Seattle, WA, 10/20 (virtual).

Updates in Treatment of Early Stage and Locally Advanced Non-Small Cell Lung Cancer. 16th Annual California Cancer Consortium, Pasadena, CA, 10/20 (virtual).

Matching Drugs to Targets in NSCLC. Practical Recommendations in Immuno and Molecular Oncology (PRIMO). 2/21 (virtual).

Antibody-Drug Conjugates in Lung Cancer. Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Antibody-Drug Conjugate Meeting. 2/21 (virtual).

Endpoints at #ASCO21: The 2021 Cancer R&D Spotlight, 6/21 (virtual)

Best of Precision Medicine 2021. Debate: Precision therapies should NOT only be adopted based on the results of randomized phase 3 trials. 10/21 (virtual)

Detection & Clinical Application of Minimal Residual Disease in Lung Cancer. Seattle Multidisciplinary Lung Conference, Seattle, WA, 11/21 (live, in person)

Social Media Use in Medicine, ASTRO Multidisciplinary Thoracic Cancers Symposium, Phoenix, AZ, 12/21 (live, in person)

Highlights & Open Questions in Non-Small Cell Lung Cancer, 2021 OncoAlert Colloquium, 1/22 (virtual)

Immunotherapy and other Novel Combinations, Expert Panel. IASLC Targeted Therapies in Lung Cancer, 2/22 (virtual)

Lung Adenocarcinoma Updates, Evolving Treatments for Oncology Practice: How the Masters Treat Cancer, 2/22 (virtual)

Telemedicine for Cancer After the COVID-19 Pandemic: Lessons Learned. 2022 Summit on Cancer Health Disparities, Seattle, WA, 4/22

KEYNOTE-189 and IMpower150, International Summit on Lung Cancer, Rome, Italy, 5/22 (virtual presentation)

Telemedicine in Cancer Care After the COVID-19 Pandemic (Keynote address), 2022 Update in Lung Cancer Management Symposium, Milwaukee, WI, 8/22

The Value of Immunotherapy in mNSCLC: Past, Now, and Next: National Immuno-Oncology Master Class in Lung Cancer, 2022, Jakarta, Indonesia (virtual), 8/22

The Future of Telemedicine in Cancer Care, California Cancer Consortium, Pasadena, CA, 8/22

Current and Debated Standards in EGFR and ALK+ NSCLC. 10th All-Ireland Lung Cancer Conference, Dublin, Ireland, 9/22

Debate: The ADAURA Wars: Osimertinib is a new standard of care for early stage EGFR mutant NSCLC (for). 10th All-Ireland Lung Cancer Conference, Dublin, Ireland, 9/22

Social Media and Thoracic Oncology: Keeping Up to Date, Keeping Up with the Joneses. 10th All-Ireland Lung Cancer Conference, Dublin, Ireland, 9/22

Progress Report: AccessHope Building Momentum. City of Hope Medical Oncology Department Symposium, Virtual, 10/22

Disparities in Precision Oncology and Improving Access to Evidence-Based Testing for Targeted Therapies. Precision Oncology Summit, Salt Lake City, UT, 10/22

Developments in Peri-operative Systemic Therapy in Advanced NSCLC, Seattle Multidisciplinary Thoracic Oncology Conference, Seattle, WA 10/22

Telehealth: Pros, Cons, & Pitfalls (KEYNOTE), Multidisciplinary Approach to Cancer Symposium, Las Vegas, NV 11/22

Controversies in Non-Small Cell Lung Cancer, 2021 OncoAlert Colloquium, 1/23 (virtual)

Consolidation Targeted Therapies in Unresectable Stage III NSCLC. Targeted Therapies in Lung Cancer IASLC Conference. Santa Monica, CA, 2/23.

Telemedicine in Oncology: Natural Fit or Arranged Marriage? Texas Lung Cancer Conference, Austin, TX, 3/2023.

Expert Case Panel in Thoracic Oncology. PrecisCa Fellows Forum & Faculty Retreat, Miami, FL 4/2023.

Online Learning and Maintaining a Digital Presence: Social Media in Oncology. PrecisCa Fellows Forum & Faculty Retreat, Miami, FL 4/2023.

Sessions Chaired

Pacific Northwest Thoracic Oncology Symposium, (CME), Seattle, WA, 4/04

Multidisciplinary Interactive Thoracic Oncology Conference (CME), Seattle, WA; 4/05

Multidisciplinary Interactive Thoracic Oncology Conference (CME), Seattle, WA; 5/05

Multidisciplinary Interactive Thoracic Oncology Conference (CME), Seattle, WA; 4/06

Emerging Trends in Oncology (CME), Seattle, WA, 7/06

Multidisciplinary Interactive Thoracic Oncology Conference (CME), Seattle, WA; 5/07

Multidisciplinary Interactive Thoracic Oncology Conference (CME), Seattle, WA; 4/08

Current Trends in Lung Cancer and Head & Neck Cancer, Seattle, WA, 3/2009

Multidisciplinary Interactive Thoracic Oncology Conference (CME), Seattle, WA; 5/09

Challenges and Opportunities in Patient-Centered Care: Where Are We Now, and Where Are We Going, Chicago, IL, 12/13

GRACE Patient Forum on Acquired Resistance to Targeted Therapies in Lung Cancer, Boston, MA, 9/14

GRACE Patient Forum on Immunotherapy for Melanoma, Lung, and Renal Cancers, Chicago, IL, 10/14

Clinical Care Options, Integrating the New Paradigm of Immuno-Oncology into NSCLC Management (CME), Denver, CO, 9/15

GRACE Patient Forum on Acquired Resistance to Targeted Therapies in Lung Cancer, San Francisco, CA, 11/15

Immunotherapies for Advanced NSCLC: Current State of the Field (CME): Atlanta Cancer Symposium, Atlanta, GA, 8/2016

Biomedical Learning Institute, Personalized Therapies in Lung Cancer, San Francisco, CA, 10/16

Biomedical Learning Institute, Lung Cancer Master Class, Dallas, TX, 3/17

OncLive State of the Science, NSCLC, Seattle, WA, 4/17

Immune Checkpoint Inhibitors in NSCLC Care: Experts Address Clinical Challenges to Clarify Optimal Use, ASCO (CME), Chicago, IL, 6/17
 Lung Cancer Expert Summit, Washington, DC, 6/17
 Clinical Care Options, Immune Checkpoint Blockade in NSCLC: Expert Perspectives on Current Standards and the Next Frontier (CME) Chicago, IL, 6/18
 Lung Cancer Expert Summit, Dallas, TX 6/18
 Controversies in first-line management of EGFR mutant NSCLC: Presence of CNS metastases. EGFR Mutant NSCLC: Evolving Treatment Paradigms and Game Changers for Current and Future Front-Line Care (CME), Toronto, ON, Canada, 9/18
 Biomedical Learning Institute, Lung Cancer Master Class, Dallas, TX, 10/18
 Locally advanced and metastatic NSCLC Immersion Summit, Seattle, WA, 1/19
 Immunotherapy combinations for lung cancers: Challenges and opportunities of rapidly evolving treatments (CME). Atlanta, GA, 3/19
 Evolution in the Care of NSCLC: Keeping Pace with Today's Best Practices (CME), Chicago, IL, 6/19
 1st Annual Lung Cancer Expert Summit, Dallas, TX, 6/19
 Lung Cancer Community Oncology Summit, Dallas, TX, 7/19
 Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How? (CME). Phoenix, AZ, 9/19
 OncTalk: Case-Based Panel Discussions in NSCLC. San Francisco, CA, 11/19.
 2020 Thoracic Oncology Summit: Bridging the Gaps Limiting Molecular Testing and Treatments in Broad Clinical Practice. Virtual/online, 8/20.
 2nd Annual Lung Cancer Expert Summit, Virtual/online, 6/20.
 3rd Annual Lung Cancer Expert Summit, Virtual/online, 6/21.
 OncTalk: Case-Based Panel Discussions in NSCLC, Virtual/online, 12/21.
 Technology & Cancer Care Disparities, Summit on Cancer Health Disparities, Seattle, WA, 4/22
 4th Annual Lung Cancer Expert Summit, Dallas, TX, 10/22
 Seattle Multidisciplinary Thoracic Oncology Conference, Seattle, WA, 10/22
 Second International Summit on Lung Cancer, Rome, Italy, 5/23

VIII. PUBLICATIONS

Publications (peer-reviewed): 54 total published

1. **West HL**, Mark GP, & Hoebel, BG. Effects of conditioned taste aversion on extracellular serotonin in the lateral hypothalamus and hippocampus of freely moving rats. *Brain Res* 556: 95-100, 1991.
2. Marston HM, **West HL**, Wilkinson, LJ, Everitt BJ, & Robbins TW. Effects of cytotoxic lesions of the medial septum and vertical limb nucleus of the diagonal band of Broca on conditional visual discrimination: Relationship between discrimination performance and choline acetyltransferase activity in the cingulate cortex. *J Neurosci*, 14:2009-2019, 1994.
3. **West HL**, Rebeck GW, & Hyman BT. Frequency of the apolipoprotein E e2 allele is diminished in sporadic Alzheimer's disease. *Neurosci Lett* 175: 46-48, 1994.
4. Rebeck GW, Perls TP, **West HL**, Sodhi P, Lipsitz LA, & Hyman BT. Reduced apolipoprotein e4 allele frequency in the oldest old Alzheimer's patients and cognitively normal patients. *Neurol*, 44: 1513-1516, 1994.
5. Hyman BT, **West HL**, Rebeck GW, Lai F, & Mann DMA. Neuropathological changes in Down's syndrome hippocampal formation: effect of age and apolipoprotein E genotype. *Arch Neurol* 52: 373-378, 1995.
6. Hyman BT, **West HL**, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, & Stanley HE. Quantitative analysis of senile plaques in Alzheimer's disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21(Down syndrome). *Proc Nat Acad Sci USA* 92: 3586-3590, 1995.

7. Gomez-Isla T, **West HL**, Rebeck GW, Harr SD, Growden JH, Locasio JT, Perls T, Lipsitz, LA, & Hyman BT. Clinical and pathological correlates of apolipoprotein E e4 in Alzheimer's disease. *Ann Neurol* 39: 62-70, 1996.
8. Gomez-Isla T, Hollister R, **West H**, Mui S, Growdon JH, Petersen RC, Parisi JE, & Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann Neurol* 41: 17-24, 1997.
9. Gandara DR, **West H**, Chansky K, Davies AM, Lau DHM, Crowley J, Gumerlock PH, & Franklin W. Bronchioloalveolar carcinoma: A model for investigating the biology of EGFR Inhibition. *Clin Cancer Res* 10: 4205s-4209s, 2004.
10. **West HL**, Crowley JJ, Vance RB, Franklin WA, Livingston RB, Dakhil SR, Giguere JK, Rivkin SE, Kraut M, Chansky K, & Gandara DR. Advanced bronchioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714). *Ann Oncol* 16: 1076-1080, 2005.
11. Hirsch FR, Varella-Garcia M, McCoy J, **West H**, Xavier, AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, & Gandara DR. Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). *J Clin Oncol* 2005; 23: 6838-6845, 2005.
12. **West HL**, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, & Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. *J Clin Oncol* 24: 1807-1813, 2006.
13. Nemunaitis J, Meyers T, Senzer N, Cunningham C, **West H**, Vallieres E, Anthhony S, Vukelja S, Berman, B, Tully H, Pappen BV, Sarmiento S, Arzaga R, Duniho S, Engardt S, Meagher M, & Cheever MA. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. *Molec Ther*, 13: 1185-91, 2006.
14. Hirsch F, Varella-Garcia M, Capuzzo F, McCoy J, Bemis L, Xamier A, Dziadziuszko R, Gumerlock P, Chansky K, **West H**, Gazdar A, Crino L, Gandara D, Franklin W, & Bunn P, Jr. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. *Ann Oncol* 18:752-760, 2007.
15. Chen G, Huynh H, Fehrenbacher L, **West H**, Lara, PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, & Lau D. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. *J Clin Oncol* 27: 1401 – 1404, 2009.
16. **West HL**, Wakelee HA, Perry MC, Belt RJ, Chen R, & Obasaju C. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small cell lung cancer: A phase II clinical trial. *Ann Oncol* 20: 850 -856, 2009.
17. Green, MR. **West H**, & Socinski, MA. Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer. *J Thor Oncol* 4: 983-987, 2009.
18. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, **West HL**, Azada MC, Morcos PN, Lee R-M, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, & SH Ou. Safety and efficacy of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. *Lancet Oncol* 15: 1119-1128, 2014.
19. Camidge DR, Berge EM, Doebele RC, Ballas M, Jahan T, Haigentz M, Hoffman D, Spicer J, **West H**, Lee P, Yang L, Joshi A, Yurasov S, & Mita A. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small cell lung cancer. *J Thorac Oncol* 9: 1532-1539, 2014.
20. Chow H, Edelman MJ, Giaccone G, Ramalingam SS, Quill TA, Bowser AD, Mortimer J, Guerra W, Beckett LA, **West HL**, Lara PN, & Gandara DR. Impact of an interactive on-line tool on therapeutic decision-making for patients with advanced non-small-cell lung cancer. *J Thorac Oncol* 10: 1421-1429, 2015.
21. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, **West H**, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Blas B, Puig O, Henschel V, Ou S-HO. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicenter, phase 2 trial. *Lancet Oncol* 17: 234-2242, 2016.

22. Wilshire CL, Louie BE, Horton MP, Castiglioni M, Aye RW, Farivar AS, **West HL**, Gorden JA, & Vallières E. Comparison of outcomes for patients with lepidic pulmonary adenocarcinoma defined by twostaging systems: A North American experience. *J Thorac Cardiovasc Surg* 151: 1561-1568, 2016.
23. Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, Hansen KH, Kim S-W, Huber RM, **West HL**, Groen JM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz Arez Rodriguez LG, Smit, EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized multicenter phase II trial. *J Clin Oncol* 35: 2490-2498, 2017.
24. Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, **West H**, Ko A, Ong JT, Trunova N, Gridelli C. Nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. *Lung Cancer: Targ Ther* 8: 207-216, 2017.
25. **West H**, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, & Gandara DR. Paired phase II studies of erlotinib/ bevacizumab in advanced bronchioloalveolar carcinoma or in never-smokers with advanced non-small-cell lung cancer (NSCLC): SWOG S0635 and S0636 trials. *Clin Lung Cancer* 19: 84-92, 2018.
26. Gaspar LE, **West HJ**, Addario BJ, Camidge DR. The patient experience with shared decision-making in lung cancer: a survey of patients, significant others or cancer givers. *Patient Exper J* 5, 2018. DOI: 10.35680/2372-0247.1241
27. Camidge DR, Kim D-W, Tiseo M, Langer CJ, Ahn M-J, Shaw AT, Huber RM, Hochmair MJ, Lee, DH, Bazhenova LA, Gold KA, Ou S-HI, **West HL**, Reichmann W, Haney J, Clackson T, Kerstein D, & Gettinger SN. Exploratory analysis of brigatinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. *J Clin Oncol* 36: 2693-2701, 2018
28. **West H**, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp H-G, Daniel D, McCune S, Tekhail T, Zer A, Reinsmuth N, Sadiz A, Sandler A, Lin W, Lohmann TO, Archer V, Wang L, Kowanetz M, & Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel, compared with carboplatin plus nab-paclitaxel for first line treatment of metastatic non-squamous NSCLC (IMpower130): a phase 3 study. *Lancet Oncol* 20: 924-937, 2019.
29. Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, Borghaei H, **West HJ**, Kirpalani P, Morris D, Lee C, Pecot CV, Zagat T, Stinchcombe T, Pennell N. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. *Cancer Treatment Res Comm* 19, 2019. doi.org/10.1016/j.jctarc.2019.100126.
30. Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T, Dingemans M, Liu SV, Peled N, Pennell NA, Reck M, Rolfo C, Tan D, Vansteenkiste J, **West H**, & Besse B. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of $\geq 1\%$ by the U.S. Food and Drug Administration. *Ann Oncol* 30: 1686-1688, 2019.
31. Oxnard GR, **West H**, King JC. Improving molecular oncology by making results available to patients. *JAMA Onc* 5: 1689-1690, 2019.
32. Weiss JM, Pennell N, Deal AM, Morgensztern D, Bradford DS, Crane J, **West HJ**, Lee C, Pecot C, Stevenson JP, Irvin W, Socinski M, Stinchcombe T, Villaruz LC, & Muss HB. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. *Cancer* 126: 1060-1067, 2020.
33. Huber RM, Hansen KH, Paz-Arez LR, **West HL**, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MH, Kim ES, Kerstein D, Groen HJM, Camidge DR. Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial. *J Thorac Oncol* 15: 404-415, 2020.
34. Gyawali BG & **West HJ**. Lessons from ADAURA on adjuvant cancer drug trials: evidence, ethics, and economics. *J Clin Oncol* 2020. doi: 10.1200/JCO20.01762
35. Spigel Dr, Jotte RM, Aix SP, Gressot L, Morgensztern D, McCleod M, Socinski MA, Daniel D, Juan-Vidal O, Mileham KF, **West H**, Page R, Reinmuth N, Knoble J, Chen T Bhore R, Wofsteiner W, Ong TJ, Gridelli C, Thomas M. Nanoparticle albumin-bound paclitaxel plus carboplatin induction followed

- by nanoparticle albumin-bound paclitaxel maintenance in squamous non-small-cell lung cancer (ABOUND.sqm): a phase III randomized trial. *Clin Lung Cancer* 22: 6-15, 2021.
36. Nishio M, Barlesi F, **West H**, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi f, Sanborn RE, Szalai Z, Ursol G, Mendus D, Wang L, Wen C, McClelland M, Hoang T, Phan S, Socinski MA. Atezolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer: results from the randomized phase III IMpower132 trial. *J Thorac Oncol* 16: 653-664, 2021.
 37. **West HJ** & Gyawali BG. Why not adore ADAURA? The trial we needed vs. the trial we got. *JAMA Oncol*, Published online, 2021. doi:10.1001/jamaoncol.2020.6752
 38. Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova, Zhu VW, **West HL**, Mekhail T, Genzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Janne PA. Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with *EGFR* exon 20 insertion mutation from a phase 1/2 trial. *Cancer Discov*, 2021. doi: 10.1158/2159-8290.CD-20-1598.
 39. Ehrhunmwunsee L, Wing SE, Shen J, Hu H, Sosa E, Lopez LN, Raquel C, Sur M, Ibarra-Noriega P, Currey M, Lee J, Kim JY, Raz DJ, Amini A, Sampath S, Koczywas M, Massarelli E, **West HL**, Reckamp KL, Kittles RA, Salgia R, Seewaldt VL, Neuhausen SL, Gray SW. *Cancer Epidemiol Biomarkers Prev*, 2021. doi: 10.1158/1055-9965.EPI-20-1555.
 40. **West HJ**, Tan AT, Barzi A, Wong D, Parsley R, Sachs T. A novel program offering remote, asynchronous subspecialist input in thoracic oncology: early experience and insights gained during the COVID-19 pandemic. *JCO Oncol Practice*, 2021. doi: 10.1200/OP.21.00339
 41. **West H**, McClelland M, Cappuzo F, Reck M, Mok TSK, Jotte RM, Nishio M, Kim E, Morris S, Zou W, Shames DS, Thakur MD, Shankar G, Socinski M. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-Mutated non-small cell lung cancer with STK11, KRAP1, or TP53 co-mutations. Subgroup results from the phase III IMpower150 trial. *J Immunother Cancer*, 2022. doi: 10.1136/jitc-2021-003027.
 42. Liu J, Bratton E, Yu X, Ladbury C, Wagner J, **West H**, Massarelli E, Salgia R, Pathak R, Villafior V, Villalona-Calero M, & Amini A. Patters of care in maintenance therapy in US patients undergoing definitive chemoradiation for stage 3 non-small cell lung cancer (NSCLC). *Am J Clin Oncol* 45: 49-54, 2022.
 43. Morgan G, Agarwal N, Choueiri T, Dizon D, Hamilton E, Markham MG, Lewis M, Prowell T, Rugo HS, Subbiah V, & **West HJ**. The (r)evolution of social media in oncology: engage, enlighten, and encourage. *Cancer Discov* 12: 1620-1624, 2022.
 44. Giunta EF, Signori A, **West HJ**, Metro G, Friendlaender A, Parikh K, Banna GL, Addeo A. Beyond crizotinib: a systematic review and meta-analysis of the next-generation ALK inhibitors as first line treatment for ALK-translocated lung cancer. *Front Oncol* 2022. Website: <https://www.frontiersin.org/articles/10.3389/fonc.2022.921854/abstract>
 45. Gettinger SN, Huber RM, Kim D-W, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz Ares Rodriguez LG, **West HL**, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim S-W, Ahn M-J, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. *J Thorac Oncol Clin Res Rep*, 2022, website: <https://www.jtocrr.org/action/showPdf?pii=S2666-3643%2822%2900109-6>. <https://doi.org/10.1016/j.jtocrr.2022.100385>.
 46. Novak J, Salgia R, **West H**, Villalona-Calero MA, Sampath S, Williams T, Villafior V, Massarelli E, Rathak R, Koczywas M, Chau B, Amini A. Ablative radiotherapy as a strategy to overcome TKI resistance in EGFR-mutated NSCLC. *Cancers* 2022. <https://doi.org/10.3390/cancers1413983>.
 47. **West H**, Hu X, Zhang S, Song Y, Chirovsky D, Gao X, Lerner A, Jiang A, Signorovitch J, Samkari A. Treatment patterns and outcomes in resected early-stage non-small cell lung cancer: an analysis of the

SEER-Medicare data. *Clin Lung Cancer* 2022. Website: <https://www.clinical-lung-cancer.com/action/showPdf?pii=S1525-7304%2822%2900290-X>

48. Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, Finley GG, Kaul MD, Yu W, Paranthaman N, Baira I, & **West HJ**. Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. *JAMA Oncol*, 2023, online: <https://jamanetwork.com/journals/jamaoncology/fullarticle/2801588>
49. **West HJ**, Hu X, Chirovsky D, Walker MS, Wang Y, Kaushiva A, Tepsick J, & Samkari A. Clinical and economic impact of recurrence in early-stage non-small cell lung cancer following complete resection. *Future Oncology*, 2023, online: <https://www.futuremedicine.com/doi/10.2217/FON-2023-0024>.
50. Uprety D, Zhu D, & **West HJ**. ChatGPT – a promising generative AI tool and its implications on cancer care. *Cancer* 2023, <https://doi.org/10.1002/cnccr.34827>
51. Liu J, **West H**, McGee HM, Williams TM, Lee P, Amini A. Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review. *Neoplasia*, 2023. Online: <https://doi.org/10.1016/j.neo.2023.100914>
52. Liu J, Amini A, Govindarajan A, Abuali T, Mambetsarierv I, Massarelli E, Villafior V, Villalona-Calero M, **West H**, Williams T, & Salgia R. Targeted therapies in early-stage resectable non-small-cell lung cancer: new kids on the block. *JCO Precis Oncol*, 2023, online: <https://doi.org/10.1200/PO.22.00445>
53. Barzi A, Kim AJ, Liang CK, **West H**, Wong DA, Wright C, Nathwani N, Vasko CM, Chung V, Robinson DA, & Sachs T. Pancreatic adenocarcinoma, real world evidence of care delivery in AccessHope data. *J Person Med* 13, 1377. Online: <https://doi.org/10.3390/jpm13091377>
54. **West HJ**, Wong DA, Nathwani N, Wright C, Liang C, Sachs TM, & Barzi A. Network-facilitated rapid growth of a US-based remote asynchronous oncology subspecialist case review service. *Internat J Cancer Care Delivery*, 2023, in press.

Publications (review articles/invited papers): 35 Total

1. Hoebel BG, Mark GP, & **West HL**. Conditioned neurotransmitter release. Symposium on Regulation of Food Intake, Metabolism, and Energy Balance 4: 36-42, 1990.
2. Hernandez L, Parada M, Baptista T, Schwartz D, **West HL**, Mark GP, & Hoebel BG. Hypothalamic serotonin in treatments for feeding disorders and depression as studied by brain microdialysis. *J Clin Psych* 52 (Suppl.): 32-40, 1991.
3. Hyman BT, Gomez-Isla T, **West H**, Briggs M, Chung H, Growden JH, & Rebeck GW. Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease: Window on molecular epidemiology. *Ann New York Acad Sci* 777: 158-165, 1996.
4. Hyman BT, Hedley-Whyte ET, Rebeck GW, Vonsattel JP, **West HL**, & Growdon JH. Apolipoprotein E4/4 in a neuropathologically normal very elderly individual. *Arch Neurol* 1996; 53: 215.
5. Hyman BT, Gomez-Isla T, Rebeck GW, Briggs M, Chung H, **West HL**, Greenberg S, Mui S, Nichols S, Wallace R, & Growdon JH. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. *Ann New York Acad Sci* 802: 1-5, 1996.
6. Disis ML, **West HL**, & Schiffman K. Cancer vaccines for the treatment and prevention of non-small cell lung cancer. *Clin Lung Cancer* 1: 294-301, 2000.
7. Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, & **West HL**. Myalgias & arthralgias associated with paclitaxel: A review of incidence and management. *Oncol* 17: 271-277, 2003.
8. Gandara DR, **West H**, Albain KS, Werner-Wasik M, Crowley J, & Choy H. Defining the role of radiation therapy in Stage III non-small cell lung cancer: Rationale and design of a new intergroup study. American Society of Clinical Oncology 40th Annual Meeting Educational Book. pp. 458-462, 2004.

9. **West H** & Albain KS. Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer. *Semin Oncol* 32: 284-292, 2005.
10. **West H**. Emerging approaches to advanced bronchioloalveolar carcinoma. *Curr Treat Opt Oncol* 7: 69-76, 2006.
11. Kris MG, Giaccone G, Davies A, Fukuoka M, Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Van Meerbeeck JP, & **West H**. Systemic therapy of bronchioloalveolar carcinoma: results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma. *J Thorac Oncol* 1: S32-S36, 2006.
12. **West, H**. Gefitinib in advanced bronchioloalveolar carcinoma (BAC): A case study and review of clinical research on EGFR tyrosine kinase inhibitor therapy for BAC. *Am J Heme/Oncol* 5 (suppl 10): 9-12, 2006.
13. **West H**. Designs with targeted therapies. *J Thorac Oncol* 2: S291, 2007.
14. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, **West H**, & Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. *J Thor Oncol* 3: 545-555, 2008.
15. Garfield DH, Cadranel J, & **West HL**. Bronchioloalveolar carcinoma: The case for two diseases. *Clinical Lung Cancer* 9: 24-29, 2008.
16. **West H**, Harpole D, & Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. *CHEST* 136; 1112-1118, 2009.
17. Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam, Reckamp K, Simon G, Tsao M, **West HJ**, Herbst R, Johnson D, Bunn P, & Govindan R. Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. *J Thorac Oncol* 4: 930-935, 2009.
18. **West H**, Lilenbaum R, Harpole D, Wozniak A, & Sequist L.. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. *J Thor Oncol* 4 (suppl 2): S1025-1028, 2009.
19. **West H**. The evolving role of targeted therapy in early stage and locally advanced non-small cell lung cancer. *Curr Oncol Rep* 13: 280-289, 2011.
20. **West H**, deBronkart D, & Demetri GD. A New Model: Physician-Patient Collaboration in Online Communities and the Clinical Practice of Oncology. *ASCO Ed Book* pp. 443-448, 2012.
21. **West H**, Oxnard GR, & Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer. New strategies and new agents. *ASCO Ed Book* pp. 272-278, 2013.
22. **West H**. Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity. *Clin Adv Hem Onc* 12: 593-600, 2014.
23. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Knudson M, Ramalingam SS, **West H**, Whitlock S, & Somerfield MR. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the American Pathologists/ International Society for the Study of Lung Cancer/ Association of Molecular Pathologists guideline. *J Clin Oncol* 32: 3673-3679, 2014.
24. Pennell NA, Arcila ME, Gandara DR, & **West H**. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. *ASCO Ed Book* 39: 531-542, 2019.
25. **West H**. Treatment of oligometastatic disease in non-small cell lung cancer. *Clin Chest Med* 41: 249-258, 2020.
26. **West H**. An embarrassment of riches: what is the optimal path for first line therapy of EGFR⁺ advanced NSCLC? *Leading Opin Hämatologie & Onkologie* 4: 6-8, 2020.
27. **West HJ**. Telemedicine in oncology: delivering on an overdue promise in the COVID-19 era. *Frontiers Oncol* 2020. Published online: <https://doi.org/10.3389/fonc.2020.578888>.

28. **West H.** ADAURA: a definitive answer to the wrong question. *Precis Cancer Med*, 2020. <https://dx.doi.org/10/21037/pcm-2020-mnslc-02>
29. **West HJ**, Barzi A, & Wong D. Telemedicine in cancer care beyond the COVID-19 pandemic: oncology 2.0? *Current Oncol Reports*, 2022. <https://doi.org/10.1007/s11912-022-012332-x>
30. Desai AP, Adashek JJ, Reuss, JE, **West HJ**, & Mansfield AS. Perioperative immune checkpoint inhibition in early-stage non-small cell lung cancer: a review. *JAMA Oncol* 2022: doi: 10.1001/jamaoncol.2022.5389.
31. Uprety D & **West HJ**. Peri-operative therapy for resectable non-small-cell lung cancer: weighing options for the present and future. *JCO Oncology Practice* 2023: doi: 10.1200/OP.23.00014
32. Uprety D & **West HJ**. Maintenance of Certification (MOC): Benefit vs. burden. *JAMA* 2023: online: <https://doi.org/10/1001/jama.2023.17056>.
33. **West HJ** & Kim JY. Building the ship while sailing: rapid advances in resectable non-small cell lung cancer. *JAMA Oncol*, in press.
34. **West HJ**, Akhade A, & Gyawali G. Could we have improved upon ADAURA: refining global research practices to reduce cancer care disparities. *JCO Global Oncol*, in press.
35. West HJ & Pennell NA. Lessons from ADAURA: can we improve on a positive trial? *Cancer*: in press.

Editorials and Letters: 65 Total

1. **West H.** EGFR inhibitors fight BAC. *Signal*; 1: 18-20, 2005.
2. **West H** & Garfield DH. Bronchioloalveolar carcinoma: not as easy as “BAC”. *J Thor Oncol* 4: 1047-1048, 2009.
3. **West H.** The role for surgery in stage III non–small-cell lung cancer: Can we reliably select the right patients? *Clin Lung Cancer* 10: 314-316, 2009.
4. Stinchcombe TE & **West HL**. Maintenance therapy in non-small-cell lung cancer. *Lancet* 374: 1398-1400, 2009.
5. **West H.** Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: Incremental benefit, debatable value. *J Clin Oncol* 29: 1095-1098, 2011.
6. **West H**, & Camidge DR. Have mutation, will travel: Utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology. *J Thor Oncol* 7: 482-484, 2012.
7. **West H.** Practicing in partnership with Dr. Google: The growing effect of social media in oncology practice and research. *Oncologist* 18: 780-782, 2013.
8. **West H.** Patients with advanced non-small-cell lung cancer and marginal performance status: Walking the tight rope toward improved survival. *J Clin Oncol* 31: 2841-2843, 2013.
9. **West H.** Afatinib for advanced mutation NSCLC: New hope or new Coke? *J Commun Supp Oncol* 12: 115-117, 2014.
10. **West H.** Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy? *Trans Lung Cancer Res* 3: 400-402, 2014.
11. **West H.** The failure of figitumumab: the danger of taking shortcuts in drug development. *Ann Oncol* 26: 447-448, 2015.
12. **West H.** Individualizing adjuvant therapy for early stage non-small cell lung cancer: we see the destination, but we don’t yet know the route. *J Thorac Dis* 7: 235-237; 2015.
13. **West H.** Immune checkpoint inhibitors. *JAMA Oncol* 1: 115, 2015
14. **West H.** Malignant pleural effusions. *JAMA Oncol* 1: 260, 2015.
15. **West H.** Circulating tumor cells. *JAMA Oncol* 1: 394, 2015.
16. **West H** & Jin J. Neoadjuvant therapy. *JAMA Oncol* 1: 550, 2015.
17. **West H** & Jin J. Adjuvant therapy. *JAMA Oncol* 1: 698, 2015.
18. **West H** & Jin J. The evolution of a cancer. *JAMA Onc* 1: 850, 2015.
19. **West H** & Jin J. Performance status in patients with cancer. *JAMA Onc* 1: 998, 2015.
20. **West H** & Jin J. Transarterial chemoembolization. *JAMA Oncol* 1: 1178, 2015.

21. **West H.** The slippery slope of broadening eligibility and weak endpoints: defending the *oligo* in oligometastatic non-small cell lung cancer. *JAMA Oncol* 1: 1219-1220, 2015.
22. **West H.** Balancing benefit, risk, and time to new cancer therapies. *JAMA Oncol* 2016, 2: 122.
23. **West H** & Jin J. Portacaths. *JAMA Oncol* 2: 152, 2016.
24. Bates G, Taub R, & **West H.** Fertility and cancer treatment. *JAMA Oncol* 2: 284, 20156.
25. **West H.** Young patients with lung cancer – an understudied population. *JAMA Oncol* 2: 321, 2016.
26. Subbiah V & **West HL.** Bone complications in patients with cancer. *JAMA Oncol* 2: 695, 2016.
27. **West H.** No solid evidence, only a hollow argument for universal tumor sequencing; Show me the data. *JAMA Oncol* 2: 717-718, 2016.
28. **West H** & Jin J. Lymph nodes and lymphadenopathy. *JAMA Oncol* 2: 971, 2016.
29. Subbiah V & **West HL.** Jaundice (hyperbilirubinemia) in cancer. *JAMA Oncol* 2: 1236, 2016.
30. **West H.** Can we define and reach precise goals for precision medicine in cancer care? *J Clin Oncol* 34: 3595-3597, 2016.
31. Gupta A & **West H.** Mucositis (or stomatitis). *JAMA Oncol* 2: 1379, 2016.
32. **West H.** Highlights of recent studies of metastatic non-small cell lung cancer. *JAMA Oncol* 3: 159-160, 2017.
33. **West H.** Bringing adjuvant chemotherapy for resected non-small cell lung cancer into real-world practice: Better late than never? *JAMA Oncol* 3: 619, 2017.
34. **West H.** Do the data on scalp cooling for patients with breast cancer warrant broad adoption? *JAMA Oncol* 3: 1147, 2017.
35. West H. Chemotherapy-induced hair loss (alopecia). *JAMA Oncol* 3: 1147, 2017.
36. Pagel J & **West H.** Chimeric antigen receptor T-cell as cancer therapy. *JAMA Oncol* 3: 1595, 2017.
37. Patel S & **West H.** Febrile neutropenia. *JAMA Oncol* 3: 1751, 2017.
38. **West H.** Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. *Ann Transl Med* 5: 371-379, 2017.
39. **West H.** Complementary and alternative medicine. *JAMA Oncol* 4: 1147, 2018.
40. Gupta A, Wolfe HR, & **West H.** I have neutropenia – what do I need to know? *JAMA Oncol* 4: 1307, 2018.
41. **West H.** Redefining the value proposition of precision oncology: can we integrate genomic testing without overselling it? *JAMA Oncol* 4: 1423-1424, 2018.
42. **West H** & Dahlberg S. Clinical trials, endpoints, and statistics. Measuring and comparing clinical treatments in practice. *JAMA Oncol* 4: 1798, 2018.
43. Gyawali B & **West H.** Plasma vs tissue next-generation sequencing in non-small cell lung cancer – either, both, or neither? *JAMA Oncol* 5: 148-149, 2019.
44. Ewalt MD, **West H,** & Aisner DL. Next generation sequencing – testing multiple genetic markers at once. *JAMA Oncol* 5: 1076, 2019.
45. **West H.** Online cancer information and patient groups. *JAMA Oncol* 5: 1376, 2019.
46. Walko C & **West H.** Antibody-drug conjugates in cancer. *JAMA Oncol* 5: 1076, 2019.
47. Shohdy KS & **West H.** Circulating tumor DNA testing – liquid biopsy of a cancer. *JAMA Oncol* 6: 792, 2020
48. Patel A & **West H.** What does my stage of cancer mean? *JAMA Oncol*, 2020, online. doi: 10.1001/jamaoncol/2020.1592
49. **West HJ.** Jarring discordance between idealized and real-world management in stage III non-small-cell lung cancer. *JCO Oncol Practice* 16: 628-630, 2020.
50. **West H.** Prognostic models for immunotherapy: emerging factors for an evolving treatment landscape. *Transl Lung Cancer Res* 10: 9-12, 2021.
51. Fusco MJ, **West HJ,** & Walko CM. Tumor mutational burden and cancer treatment. *JAMA Oncol* 7: 316, 2021.
52. **West HJ.** When the signal from phase 2 research should be a warning sign. *JAMA Oncol* 7: 394, 2021.
53. **West HJ,** Naqash AR. Why are randomization and placebos included in many cancer trials? *JAMA Oncol*, 2021. doi:10.1001/jamaoncol.2021.0896

54. Presant CA, Macalintal J, Ashing KT, Yeung S, Tiep B, **West H**, Merla A, & Phillips T. Tragic triad of tobacco dependence, cancer, and COVID-19 pandemic: an urgent call for attention by health care systems and professionals. *JCO Oncol Pract* 2022. doi: 10.1200/OP.21.00625
55. Liu J, Ladbury C, Kim J, Raz D, Erhunmwunsee L, **West HJ**, Williams T, Salgia R, Massarelli E, Amini A. Controversies in thoracic oncology: “Post-operative radiation therapy should be used for completely resected stage III-N2 non-small cell lung cancer in select patients.” *J Thorac Oncol* 17: 194-196, 2022.
56. **West H**. Moving beyond feasibility: current and future questions for telemedicine research in oncology. *JAMA Netw Open* 5: e2220550, 2022. doi:10.1001/jamanetworkopen.2022.20550.
57. Desai A, Velazquez AI, & **West HJ**. Perioperative therapy in early stage lung cancer. *JAMA Oncol* 2022, online: doi:10.1001/jamaoncol.2022.1940.
58. Singhi EK, Feldman J, & **West HJ**. The multidisciplinary cancer conference. *JAMA Oncol* 2022, online: doi:10.1001/jamaoncol.2022.4924.
59. Turgeman I & **West HJ**. Adolescents and young adults with cancer. *JAMA Oncol* 2023, online: <https://jamanetwork.com/journals/jamaoncology/fullarticle/2800540>.
60. **West HJ** & Lovly CM. Ferrying oncologists across the chasm of interpreting biomarker testing reports: systematic support needed to improve care and decrease disparities. *JCO Oncol Practice* 2023, online: doi: 10.1200/OP.23.00010
61. Aggarwal C & **West HJ**. Molecular marker testing in curable non-small cell lung cancer: practice necessarily precedes data. *JAMA Oncol* 2023, online: doi: 10.1001/jamaoncol.2023.0251
62. Desai A, Smith CJ, & **West HJ**. Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised? *Nat Rev Clin Oncol* 2023, online: doi: 10.1038/s41571-023-00761-2.
63. **West HJ**. Clinical decision making in the real world – the perfect as the enemy of the good. *JAMA Oncol* 2023, online: <https://doi:10.1001/jamaoncol.2023.1811>
64. **West HJ** & Lovly CM. Reply to J.M. Kolesar et al, J.S.Bates et al, and T.C. Knepper et al. *JCO Oncol Practice* 2023; online: doi: 10.1200/OP.23.00306.
65. **West HJ**, Bange E, & Chino FC. Telemedicine as patient-centred oncology care: will we embrace or resist disruption? *Nature Rev Clin Oncol*, 2023. Online: <https://doi.org/10.1038/s41571-023-000796-5>

Book Chapters: 8 Total

1. Mark GP, Schwartz, DH, Hernandez L, **West HL**, & Hoebel BG. Application of brain microdialysis to the study of motivation and conditioning: Measurements of dopamine and serotonin in freely-behaving rats. In: TE Robinson & JP Justice, Eds.: Microdialysis in Neuroscience. Amsterdam: Elsevier Science Publishing, pp. 131-136, 1993.
2. **West HL**, Rebeck GW, Growdon JH, & Hyman BT. Apolipoprotein E4 affects neuropathology but not clinical progression in Alzheimer’s disease. In: K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer’s disease and Related Disorders. Chichester, UK: John Wiley & Sons, pp. 363-370, 1995.
3. Hyman, BT, Sodhi, P, Harr SD, **West HL**, Simonian NA, Rebeck GW, Mui S, & Isla-Gomez T. The paradox of neurofibrillary tangles and senile plaques in Alzheimer’s disease. In: K Iqbal, JA Mortimer, B Winblad, & HM Wisniewski, Eds., Research Advances in Alzheimer’s disease and Related Disorders. Chichester, UK: John Wiley & Sons, pp. 453-460, 1995.
4. Brendel D, **West H**, Hyman S. Hallucinogens. In: D Roberts & L Friedman, Eds., Source Book of Substance Abuse and Addiction. Baltimore, MD: Williams & Wilkins, pp. 217-230, 1995.
5. **West H** & Kelly K. Pleural malignancies and benign neoplasms of the lung. In ME Hanley & C Welsh, Eds., Current Medical Diagnosis and Treatment in Pulmonary Medicine. New York: Lange Medical Books/McGraw Hill, pp. 433-439, 2003.
6. **West H**. Incorporation of novel therapies into the management of locally advanced NSCLC. In R Govindan, Ed., Locally Advanced Non-Small-Cell Lung Cancer. New York: CMP Healthcare Media, pp. 95-105, 2004.
7. **West H** & Garfield D. Bronchioloalveolar Carcinoma: New insights in epidemiology, pathology, and novel strategies. Update chapter for HI Pass, JB Mitchell, DH Johnson, AT Turrisi, & J Minna (Eds.),

Lung Cancer: Principles and Practice. Philadelphia: Lippincott, Williams, & Wilkins. Supplement, pp 1-12, 2004.

8. **West H.** Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC), In Lung Cancer, 4th Ed (Roth JA, Cox JD, Hong WK, Chang JY, Blackmon S, & Tsao A, eds.) Wiley Oxford, pp 158-175, 2013.

Published Abstracts: 70 Total

1. **West HL**, Schwartz DH, & Hoebel BG. Local injection of serotonin into the lateral hypothalamus suppresses food intake. *Soc Neurosci Abstr* 15:1281, 1989
2. **West HL**, Robbins TW, & Everitt BE. AMPA-induced cholinergic lesions of the vertical limb of the diagonal band (VDB) impair performance of a conditioned visual discrimination (CVD) task. *Soc Neurosci Abstr* 17: 138, 1991.
3. Hoebel BG, Mark GP, & **West HL**. Conditioned neurotransmitter release as measured by microdialysis. *Clin Neuropharm* 15 Suppl. 1A: 704A, 1992.
4. **West HL**, Rebeck GW, Growdon JH, & Hyman BT. Apolipoprotein E4 affects neuropathology but not clinical progression in Alzheimer's disease. *Neurobiol Aging* 15: S28, 1994.
5. Hyman BT, **West HL**, Harr S, Gomez-Isla T, & Mui S. Quantitative neuropathology in Alzheimer's disease: neuronal loss in high order association cortex parallels dementia. *Neurobiol Aging* 15: S141, 1994.
6. **West HL**, Rebeck GW, Perls T, Sodhi P, Lipsitz L, & Hyman BT. The prevalence of apolipoprotein E4 in the oldest old: connections with Alzheimer's disease. *Neurol* 44: A325, 1994.
7. **West HL**, Taylor LP, & Jacobs AD. Association of angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) with progressive sensory polyneuropathy/ataxia: a case report. *Blood* 94 (Suppl 1): 293b, 1999.
8. **West HL**, Livingston RB, Wood DE, Vallieres E, Yaziji H, & Gown A. HER-2/neu (HER2), as assessed by immunohistochemistry (IHC), is rarely expressed in stage I resected non-small cell lung cancer (NSCLC) and does not predict clinical outcome. *J Clin Oncol* 20: 333a (#1327), 2001.
9. Vallieres E, **West HL**, Hunt K, Einck J, & Stelzer K. Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant radiation therapy for malignant pleural mesothelioma: a case series. *J Clin Oncol* 20: 279b (#2867), 2001.
10. **West H**, Livingston R, Wood D, Vallieres E, Giarritta S, Yaziji H, & Gown AM. Overexpression of cyclooxygenase-2 (COX-2) is associated with more aggressive clinical behavior of non-small cell lung cancer. *Lung Cancer* 34 (Suppl 1): 45-46 (#131), 2001.
11. **West H**, Yaziji H, Giarritta S, Livingston RB, Vallieres R, Wood DE, & Gown A. Overexpression of cyclooxygenase-2 (COX-2) is associated with increased aggressiveness of non-small cell lung cancer (NSCLC) tumors. *J Clin Oncol* 2002; 21: 309a (#1235).
12. Miller DL, Vallieres EC, **West H**, Okuno SH, Marks RS. Operative morbidity and mortality after induction chemotherapy and extrapleural pneumonectomy for malignant pleural mesothelioma. *Proc Eur Assoc for Cardiothor Surg* 16 (A#1202), 2002.
13. Franklin WA, Gumerlock PH, Crowley J, Chansky K, **West H**, & Gandara DR. EGFR, HER2, and ERBB pathway activation in bronchioloalveolar carcinoma (BAC): Analysis of SWOG 9714 and lung SPORE tissue samples. *J Clin Oncol* 22: 620 (#2493), 2003.
14. Lau DHM, **West H**, Laptalo L, Geraghty E, Seibert A, Crowley J, & Gandara D. Computer-assisted image analysis of response in bronchioloalveolar carcinoma to ZD1839. *Lung Cancer* 41: S55, 2003.
15. **West HL**, Franklin WA, Gumerlock P, Vance RB, Lau DHM, Chansky K, Crowley J, McCoy J, & Gandara DR. ZD1839 (Iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG S0126. *Lung Cancer* 41: S56, 2003.
16. **West HL**, Franklin WA, Gumerlock P, Vance RB, Lau DHM, McCoy J, Crowley J, & Gandara DR. Gefitinib (ZD1839) Therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. *J Clin Oncol* 23: 618 (#7014), 2004.
17. Franklin WA, Chansky K, Gumerlock PH, Crowley J, Hirsch FR, **West H**, Crowley JJ, & Gandara DR. Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). *J Clin Oncol* 23: 619 (#7015), 2004.

18. Gold PJ, Refice S, & **West H**. Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors. *J Clin Oncol* 23: 619 (#2120), 2005.
19. Johnson BE, Ma P, **West H**, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery IW, & Heymach JV. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. *J Clin Oncol* 23: 645 (#7102), 2005.
20. Gumerlock PH, Holland WS, Chen H, Franklin WA, Hirsch FR, Mack PC, Davies AM, **West H**, & Gandara DR. Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group trial S0126 of bronchioloalveolar carcinoma (BAC) patients treated with gefitinib. *J Clin Oncol* 23: 623 (#7008), 2005.
21. Hirsch FR, Gandara DR, McCoy J, Crowley J, **West H**, Gumerlock PH, Bunn PA, Franklin WA, & Varella-Garcia M. Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). *J Clin Oncol* 23: 628 (#7030), 2005.
22. **West H**, Belt RJ, Wakelee HA, Bloss LP, Taylor L, Monberg MJ, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. *J Clin Oncol* 23: 645 (#7117), 2005.
23. Hyunh MT, Lehrenbacher L, **West H**, Davies A, Simmons J, Lara P, Yarorkovsky L, Russin M, Gandara DR, & Lau D. A multi-institution phase II trial of irinotecan and carboplatin for extensive or relapsed small cell lung cancer. *J Clin Oncol* 23: 662 (#7169), 2005.
24. Heymach J, **West H**, Kerr R, Prager D, Sandler A, Herbst R, Stewart D, Dimery I, & Johnson B. ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized phase II study. *Lung Cancer* 49 (Suppl 2): S247-248 (A#P-497), 2005.
25. Hirsch FR, Franklin WA, McCoy J, Capuzzo F, Varella-Garcia M, Witta SE, Gumerlock P, **West H**, Gandara DR, & Bunn P.A, Jr. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. *J Clin Oncol* 24: 382 (A#7072), 2006.
26. **West H**, Belt RJ, Wakelee HA, Monberg MJ, Frye LA, Ye Z, & Obasaju CK. Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical trial. *J Clin Oncol* 24: 393 (A#7116), 2006.
27. **West H**, Lee S, Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO, Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. *J Clin Oncol* 25: 430s (A#7685), 2007.
28. **West H**, Lee S, Reyno L, Fehrenbacher L, Cohn AL, Hopkins JO, Irwin DH, Smith DA, Boyd TE, & Olsen MR. DN101-004: A multicenter, open label, dose ranging study of DN-101 and docetaxel in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. *J Thor Oncol* 2(8) Suppl 4:S334 (A#B1-04), 2007.
29. Green MR, **West H**, Socinski MA, Willey J, Daniels L, Lemke K, Rafferty G, & Iovino L. Management of N3 stage IIIB NSCLC: Changes in US physician behavior following ASCO 2007. *J Clin Oncol* 26: A#7579, 2008.
30. **West H**, Chansky K, Franklin WA, Hirsch FR, Crowley JJ, Lau DH, & Gandara DR. Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. *J Clin Oncol* 26: A#8047, 2008.
31. Hanna NH, Estes D, Arnott J, Marcotte A, Hannah A, Sidor CF, **West H**, Clamon G, & Hoang T. Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 27: A#e19005, 2009.
32. Wakelee H, Gettinger S, Engelman J, Jänne P, **West H**, Subramaniam D, Leach J, Wax M, Yaron Y, & Lara P. A phase 1b/2 study of XL184 (BMS 907351) with & without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). *J Clin Oncol* 28 15s (suppl., A#3017), 2010

33. Green MR, Wozniak AJ, Willey J, Lemke KE, & **West HJ**. Plans of American medical oncologists (AMO) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC). *J Clin Oncol* 28 15s (suppl., A#7568), 2010.
34. **West H**, Moon J, Hirsch F, Mack PC, Wozniak A, Redman M, & Gandara DR. The combination of erlotinib/bevacizumab in never-smokers with advanced lung adenocarcinoma: Southwest Oncology Group (SWOG) trial 0636. *J Thor Oncol* 6 (Suppl 2:S552-553, A#MO-09-03-4), 2011.
35. **West H**, Moon J, Hirsch FR, Mack PC, Wozniak AJ, Lau D, Fehrenbacher L, Bury MJ, Redman MW, & Gandara DR. SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). *J Clin Oncol* 30 (suppl., A#7517), 2012.
36. Mack PC, Moon J, **West H**, Franklin WA, Varella-Garcia M, Wynes MW, Wozniak AJ, Redman MW, Hirsch FR, Gandara DR. Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib & bevacizumab in never-smokers with advanced NSCLC. *J Clin Oncol* 30 (suppl., A#7552), 2012.
37. Gandhi L, Shaw A, Gadgeel SM, Riely G, Cetnar J, **West H**, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter AH, Bordogna W, Balas B, Puig O, Henschel, Ou S-HI. A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an *ALK*+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). *J Clin Oncol* 33 (suppl; A#8019), 2015.
38. Spigel DR, Reckamp KL, Rizvi NA, Poddubskaya E, **West H**, Eberhardt WEE, Baas P, Antonia SJ, Pluzanski A, Vokes EE, Holgado E, Waterhouse DM, Ready N, Gainor JF, Aren OR, Horn L, Paz-Ares L, Baudelet C, Lestini BJ, Brahmer JR. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). *J Clin Oncol* 33 (suppl; A#8009), 2015.
39. Yu HA, Oxnard GR, Spira AI, Horn L, Weiss J, Feng Y, **West H**, Giaccone G, Evans TL, Kelly RJ, Fleege T, Poondru S, Jie F, Aoyama K, Foley MA, Whitcomb D, Keating AT, Krivoshik AP. Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation-positive NSCLC. *J Clin Oncol* 33 (suppl; A#8083), 2015.
40. Liu SV, Arrawal C, Carter C, Gerber DE, Gitlitz B, Horn L, Solomon B, Stinchcombe T, Villaruz L, **West H**, Kroll S, Pearce T, & Camidge Dr. A phase 2 study of tarloxotinib bromide (TH-4000) in patients with EGFR mutant, T790M-negative, advanced NSCLC progressing on an EGFR TKI. *J Thor Oncol* 10 (Suppl #2, A#P1.01-084) 2015.
41. Langer CJ, Hirsh V, Amiri K, Ko A, Knoble JL, Johnson ML, Jotte RM, McLeod M, Ong TJ, Page RD, Spigel DR, **West H**. Quality of life (QoL) by response: An interim analysis of patients (pts) with squamous (SCC) NSCLC treated with *nab*-paclitaxel/carboplatin (*nab*-P/C) induction therapy in the phase III ABOUND.sqm study. *J Clin Oncol* 34 (suppl 7S, A#63), 2016.
42. Kim D-W, Tiseo M, Ahn M-J, Reckamp RL, Hansen KH, Kim S-W, Huber RM, **West H**, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares LG, Smit EF, Kim ES, Reichmann WG, Kerstein D, Haluska FG, Camidge DR. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory *ALK*+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). *J Clin Oncol* 34, (suppl; A#9007), 2016.
43. Liu SV, Aggarwal C, Brzezniak C, Doebele RC, Gerber DE, Gitlitz B, Horn L, Solomon BJ, Stinchcombe T, Villaruz LC, **West H**, Kroll S, Pearce TE, Camidge DR. Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-mutant, T790M-negative NSCLC progression on an EGFR TKI. *J Clin Oncol* 34 (suppl; A#TPS9100), 2016.
44. Yu HA, Spira AI, Horn L, Weiss J, **West H**, Giaccone G, Evans TL, Kelly RJ, Desai BB, Krivoshik A, Fleege TE, Poondru, Jie F, Aoyama K, Whitcomb DA, Keating AT, Oxnard GR. Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer. Interim results from an ongoing phase 1 study. *J Clin Oncol* 34 (suppl; A#9050), 2016.
45. Jotte RM, Socinski MA, Reck M, Papadimitrakopoulou V, **West H**, Mok T, Sandler A, Mucci S, Coleman S, Asakawa T, Cappuzzo F. First-line atezolizumab plus chemotherapy in chemotherapy-naïve

- patients with advanced NSCLC: a phase III clinical program. *J Thorac Oncol* 11 (suppl; A#PS01.53), 2016.
46. **West H**, Nishio M, Dols MC, Saito H, Howland M, Hoang T, Deng T, Sandler A, Socinski MA. Impower132: a phase III clinical trial of 1L atezolizumab plus platinum-based chemotherapy in chemo-naïve advanced non-squamous NSCLC. *J Clin Oncol* 34 (suppl; A#TPS9101), 2017
 47. Bazhenova L, Hodgson JG, Langer CJ, Simon GR, Gettinger SN, Ou S-HI, Reckamp KL, **West H**, Chiappori A, Koh HA, Molina JR, Shaw AT, Patel JD, Favaro JP, Haney J, Reichmann W, Kerstein D, Rivera VM, Camidge DR. Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status. *J Clin Oncol* 34 (suppl; A#9065), 2017.
 48. Ou S-HI, Tiseo M, Camidge DR, Ahn M-J, Huber RM, Hochmair MJ, Kim S-W, **West HJ**, Reckamp RL, Molina JR, Liu G, Delmonte A, Ramirez SV, Bearz A, Summers YJ, Reichman W, Kerstein D, Gettinger SN, Kim D-W. Brigatinib (BRG) in patients (pts) with crizotinib (CrZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial. *J Clin Oncol* 34 (suppl; A#e20502), 2017.
 49. Cappuzzo F, Reck M, Papadimitrakopoulou V, Jotte R, **West H**, Mok T, Mocchi S, Coleman S, Asakawa T, & Socinski S. First-line atezolizumab plus chemotherapy in chemotherapy-naïve patients with advanced NSCLC: a phase III clinical program. *J Thorac Oncol* 12 (suppl; A#P3.02C-038), 2017.
 50. Huber RM, Kim D-W, Ahn M-J, Langer CJ, Tiseo M, **West H**, Groen HJM, Reckamp KL, Hochmair MJ, Leighl NB, Holmskov Hansen K, Gettinger SN, Paz-Ares LG, Kim ES, Smit EF, Kim S-W, Reichmann W, Kerstein D, & Camidge DR. Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status. *J Clin Oncol* 36 (suppl; A#9061), 2018.
 51. Pan X, Huang H, Salvatore G, Clarke S, & **West H**. ALKConnect: an anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) patient insights network: *J Thorac Oncol* 13 (suppl; A#P1.15-16), 2018.
 52. **West H**. The great oligometastatic debate: locally ablative therapies should be standard treatment for patients with oligometastases. *J Thorac Oncol* 13, 2018 (suppl; A#PC08.01), 2018.
 53. Cappuzzo F, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp H-G, Daniel D, McCune S, Mekhail T, Zer A, Kowanetz M, Lin W, Sandler A, & **West H**. IMpower130: progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. *Ann Oncol* 29 (suppl 8; A#LBA53), 2018.
 54. Janne PA, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Horn L, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, **West H**, Vincent S, Zhu J, Li S, & Riely GJ. Antitumor activity of TA-788 in NSCLC with EGFR exon 20 insertions. *J Clin Oncol* 37 (suppl; A#9007), 2019.
 55. Socinski MA, Jotte RM, Cappuzzo F, Mok TSK, **West H**, Nishio M, Papadimitrakopoulou V, Orlandi FJ, Stroyakovskiy D, Thomas CA, Nogami N, Barlesi F, Lee A, Shankar G, Yu W, Ballinger M, Bara I, Sandler A, & Reck M. IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets). *J Clin Oncol* 37 (suppl; A#9012), 2019.
 56. Neal JW, Camidge DR, Spira A, Piotrowska Z, Horn L, Costa DB, Tsao A, Patel JD, Gadgeel S, Bazhenova L, Zhu VW, **West H**, Vincent S, Zhu J, Jin S, Zhang S, Li S, Janne PA. Antitumor activity of the oral EGFR/HER2 inhibitor TAK-788 in NSCLC with EGFR exon 20 insertions. WCLC #P1.01-127, 2019
 57. Lin HM, Pan X, Biller A, Cover KJ, Huang H, Rangel V, Miller MS, **West H**. The humanistic burden of ALK+ NSCLC: findings from the ALKConnect patient insight network and research platform. WCLC #P1.01-127, 2019
 58. Spigel DR, Jotte RM, Aix SP, Gressot L, Morgensztern D, McCleod M, Socinski MA, Daniel D, Juan O, Mileham KF, **West H**, Page R, Reinmuth N, Knoble J, Tian OY, Bhore R, Wolfsteiner M, Ong TJ, Gridelli C, Thomas M. Nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): updated results of the phase III ABOUND.sqm study. WCLC #MA.13-05, 2019
 59. Lee DH, Kim D-W, Camidge DR, Langer CJ, Huber RM, Tiseo M, **West HL**, Groen HJM, Reckamp KL, Hochmair MJ, Leighl NB, Hansen KH, Gettinger SN, Rodriguez LP-A, Kim ES, Smit EF, Kim S-

- W, Ni Q, Zhang P, & Ahn M-J. Brigatinib in Asian vs. non-Asian patients with crizotinib-refractory ALK+ NSCLC in the phase 2 ALTA trial. *Ann Oncol* (suppl), 2019.
60. Cappuzzo F, Reck M, Socinski MA, Mok TSK, Jotte RM, Finley G, Rodriguez-Abreu D, Aerts JG, **West H**, Nishio M, Villaruz L, Coleman S, Lee A, Volla HK, Yu W, Sufan R, Bara I, Barlesi F. Impower150: exploratory analysis of brain metastasis development. *J Clin Oncol* 38 (supple; A#9587), 2020.
 61. **West H**, Cappuzzo F, Reck M, Mok T, Jotte R, Nishio M, Kim E, Morris S, Shankar G, Zou W, Shames DS, McClelland M, & Socinski MA. IMpower150: A post hoc analysis of efficacy outcomes in patients (pts) with KRAS, STK11, and KEAP1 mutations. *J Clin Oncol* 38 (suppl, A#9522), 2020. (withdrawn)
 62. **West H**, Cappuzzo F, Reck M, Mok T, Jotte R, Nishio M, Kim E, Morris S, Shankar G, Zou W, Shames DS, McClelland M, & Socinski MA. IMpower150: A post hoc analysis of efficacy outcomes in patients (pts) with KRAS, STK11, and KEAP1 mutations. ESMO Virtual Congress, A#1576, 2020.
 63. Riely GJ, Neal JW, Camidge DR, Spira A, Piotrowska Z, Horn L, Costa DB, Tsao A, Patel JD, Gadgeel S, Bazhenova L, Zhu VW, **West H**, Mekhail T, Gentzler R, Nguyen D, Bunn V, Jin S, Feng Z, & Jänne PA. Updated results from a phase 1/2 study of mobocertinib (TAK-788) in NSCLC with *EGFR* exon 20 insertions (exon20ins). ESMO Virtual Congress, A#1261MO, 2020.
 64. Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, Finley G, Yu W, Patel H, Paranthaman N, Bara I, **West H**. Pooled analysis of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. *J Clin Oncol* 39 (suppl; A#9002), 2021.
 65. Gettinger SN, Huber RM, Kim D-W, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares LG, **West H**, Reckamp KL, Weiss GJ, Smit EF, Hochmair M, Kim S-W, Ahn M-J, Kim ES, Groen HJM, Pye J, Vranceanu F, Camidge DR. Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): final results of the phase 1/2 and phase 2 (ALTA) trials. *J Clin Oncol* 39 (suppl; A#9071), 2021.
 66. **West H**. What evidence level is enough for approval and reimbursement of novel cancer drugs? Lessons from lung cancer. *J Thorac Oncol Proceedings from World Conference on Lung Cancer (WCLC)* 2021, #ES-13.05, p 28.
 67. **West H**, Tan AT, Barzi A, Wong D, Sachs T. A novel program offering remote, asynchronous subspecialist input in thoracic oncology: early experience during pandemic. *J Thorac Oncol Proceedings from World Conference on Lung Cancer (WCLC)* 2021, #MA12.01, p 218.
 68. **West HJ**, Hu X, Burke T, Walker MS, Wang Y, & Samkari A. Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early-stage non-small cell lung cancer (NSCLC) following complete resection. *European Lung Cancer Conference* (#89P), 2022.
 69. **West HJ**, Hu X, Burke T, Walker MS, Wang Y, & Samkari A. Disease-free survival (DFS) as a predictor of overall survival in completely resected early-stage non-small cell lung cancer. *European Lung Cancer Conference* (#90P), 2022.
 70. **West HJ**, Hu X, Burke T, Walker MS, Wang Y, & Samkari A. Real-world disease-free survival as a predictor of overall survival in resected early-stage non-small cell lung cancer. *World Conference on Lung Cancer* (EP-2.03-009), Vienna, Austria, 2022.
 71. **West HJ**, Wong DA, Nathwani N, Wright C, Liang C, Sachs TM, & Barzi A. Network-enabled growth of a US-based remote asynchronous oncologist subspecialist case review service. *J Clin Oncol* 41 (suppl 16; A#e13507), 2023.

IX. INVITED SEMINARS/LECTURES/FORUMS

- 7/04 Bronchioloalveolar carcinoma (BAC) and the epidermal growth factor receptor (EGFR) axis.
Cancer Research and Biostatistics (CRAB) Lecture Series, Seattle, WA

- 10/04 EGFR tyrosine kinase inhibitors in NSCLC. Scripps Oncology Conference. Hilton Head, SC.
- 6/05 Examining options for maintenance therapy in non-small cell lung cancer. VA Puget Sound Grand Rounds, Seattle, WA
- 9/06 Non-small cell lung cancer: Critical choices for the curable patient. Madigan Army Medical Center, Grand Rounds, McChord, WA
- 1/07 Targeted therapeutic strategies in lung cancer. Lung Cancer Affinity Group, Seattle, WA
- 9/07 Optimal second-line therapy for recurrent NSCLC. 3rd Annual Oncology Congress, San Francisco, CA
- 10/07 Adjuvant chemotherapy for resected non-small cell lung cancer. National Oncology Summit, Washington, DC
- 10/07 Current standards in extensive stage small cell lung cancer. American Society for Therapeutic Radiation and Oncology (ASTRO) Annual Conference, Los Angeles, CA
- 2/08 Role of AS 1404 in treatment of non-small cell lung cancer. Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 6/08 EGFR molecular testing in NSCLC: The argument against routine use (debate). International Lung Cancer Congress. Koloa, HI
- 8/08 Personalizing non-small cell lung cancer treatment using histology-based approaches. Hoag Hospital, Newport Beach, CA
- 11/08 Sequencing, Timing, and Duration of Therapy. Second Line Therapy and Beyond, CME educational symposium, Chicago, IL
- 4/09 EGFR inhibitors for the frontline treatment of non-small cell lung cancer. Kaiser Permanente, Walnut Creek, CA
- 6/09 Hsp90 inhibition in lung cancer: Translating from the bench to the clinic. International Lung Cancer Congress, Waikaloa, HI
- 7/09 Talk with the Doctor About Lung Cancer, Gilda's Club, Seattle, WA
- 7/10 Highlights in small cell lung cancer and stage I-III non-small cell lung cancer. Commentary presented at Best of ASCO Conference: Seattle, WA
- 6/11 Learning as if your life depends on it. Patient self-education to improve cancer care. TEDxOverlake: Redmond, WA
- 8/11 Highlights in small cell lung cancer and stage I-III non-small cell lung cancer. Best of ASCO, Seattle, WA
- 11/11 Individualizing first line and maintenance therapy strategies for advanced NSCLC, Nevada Cancer Institute Grand Rounds, Las Vegas, NV
- 2/12 Anti-tumor vaccine strategies in NSCLC. IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 6/12 Physician participation online: Adapting to a new model of interaction between doctors and engaged patients. ASCO Annual Conference: Chicago, IL
- 8/12 Ensuring personalization of care across the continuum of disease and treatment settings: Best practices in the management of advanced NSCLC. UC San Diego Nevada Cancer Institute, Las Vegas, NV
- 10/12 Changes afoot: A new model of interaction between doctors and engaged patients. LIVESTRONG REV Forum, Austin, TX.
- 6/13 The clinical perspective on acquired resistance: Identifying and overcoming barriers. ASCO Annual Conference: Chicago, IL
- 9/13 Personalized approaches in the management of advanced non-small cell lung cancer. Virginia Piper Cancer Center, Scottsdale, AZ
- 11/13 Vaccine strategies: where are we today with active immunity for NSCLC? Personalized Therapies and Best Clinical Practices for Lung Cancer. Los Angeles, CA
- 2/14 Acquired resistance to targeted therapies in advanced non-small cell lung cancer: New strategies and new agents. Scripps Hematology and Oncology Conference, La Jolla, CA
- 4/14 Non-small cell lung cancer: Essential developments in treating metastatic disease, Diablo Society of Health System Pharmacists, Walnut Creek, CA

- 6/14 Right patient, right drug, right time. Expert commentary at Metastatic Non-Small Cell Lung Cancer Oral Abstracts Session, ASCO Annual Conference: Chicago, IL
- 8/14 Highlights in metastatic non-small cell lung cancer from ASCO 2014. Best of ASCO Conference, Seattle, WA
- 11/14 A Closer Look at Personalized Treatment in the Management of Advanced NSCLC; Fall Managed Care Forum, Las Vegas, NV
- 2/15 EGFR + MEK inhibition, IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 2/15 DS-2248, IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 3/15 Transitioning survival from months to years: New developments in advanced NSCLC. Denali Oncology Group Conference, Fairbanks, AK
- 4/15 Social media as an educational and research tool in oncology. Providence Cancer Leadership council. Renton, WA
- 5/15 Biomarkers of acquired resistance: Detecting EGFR T790M in tissue and in blood; Growing Family of EGFR Inhibitors (ASCO CME Symposium), Chicago, IL
- 9/15 Oncology in a digital age: Cancer Care 2.0? Providence Cancer Leadership Council, Renton, WA
- 9/15 Management of Stage I – III NSCLC: MD Anderson Cancer Center Board Review Course, Houston, TX
- 9/15 Meet the experts: squamous cell lung cancer. 16th World Conference on Lung Cancer: Denver, CO
- 9/15 New kinase targets (expert commentary). 16th World Conference on Lung Cancer: Denver, CO
- 3/16 How immunotherapy in lung cancer is changing practice. Rush University Medical Center, Chicago, IL
- 5/16 How immunotherapy in lung cancer is changing practice. City of Hope, Duarte, CA
- 6/16 Highlights of the day: Metastatic non-small cell lung cancer. ASCO Annual Conference: Chicago, IL
- 7/16 Evolution of practice and dissemination of new data in the era of targeted therapy and social media. Best of ASCO Miami, Miami, FL
- 7/16 Advanced NSCLC: Overview of therapeutic options. Lung Cancer Master Class, Dallas, TX
- 10/16 EGFR mutation-positive NSCLC today: New options in a new therapeutic landscape. Personalized Medicine in Lung Cancer Conference, San Francisco, CA
- 11/16 Is there an optimal EGFR TKI? Examining the evidence. Chemotherapy Foundation Symposium, New York, NY
- 2/17 NSCLC overview: Clinical decision-making now and into the future. Lung Cancer Master Class, Dallas, TX
- 2/17 Immunotherapy in NSCLC: Translating trial data into clinical practice, Seattle, WA (national telecast, CME program)

- 2/17 Advanced NSCLC: So many options, how do I choose? PRIMO Annual Conference: Maui, HI
- 2/17 Changing patient/physician dynamics in the era of personalized medicine and social media. PRIMO Annual Conference: Maui, HI
- 2/17 Are we curing patients with immune checkpoint inhibitors? Yes (debate). IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 3/17 What is the optimal duration of immunotherapy for advanced NSCLC? Immune therapies for Cancer Master Class, Dallas, TX
- 4/17 Optimal treatment approaches for first-line and acquired resistance treatment of ALK-positive NSCLC. OncLive State of the Science: Seattle, WA
- 5/17 Choosing therapies for EGFR mutation-positive NSCLC. VA Southern Nevada Hospital, Las Vegas, NV
- 6/17 Immune checkpoint inhibitors in first-line therapy for advanced non-small cell lung cancer. ASCO Symposium on Immunotherapy in NSCLC, Chicago, IL
- 7/17 State of the art molecular diagnosis and targeted therapies in lung cancer, in a new world of social media. Best of ASCO Miami, Miami, FL
- 7/17 Choosing therapies for EGFR mutation-positive NSCLC. Loma Linda, CA
- 9/17 Evolving strategies for previously treated advanced NSCLC. Updates in Medical Oncology, San Francisco.
- 10/17 Immunotherapy: Critical issues in NSCLC management. Immune Therapies for Cancer Master Class, Dallas, TX
- 10/17 New targets and treatments in EGFR mutation-positive acquired resistance. IASLC 18th World Conference on Lung Cancer, Yokohama, Japan.
- 10/17 Immunotherapy for lung cancer: Breaking into a curative role? West Oncology Conference, Memphis, TN
- 11/17 What is the best treatment for advanced non-squamous NSCLC without a driver mutation? Chemotherapy Foundation Symposium, New York, NY
- 11/17 Optimal first line treatment of driver mutation-positive NSCLC: A rapidly evolving landscape. Immunotherapy and Targeted Therapies in Cancer Care, San Francisco, CA
- 1/18 Medical communication 2.0. Physician interaction with the medical and patient community. Pioneers Summit, Austin, TX
- 2/18 First line therapy in advanced NSCLC without a driver mutation: Evolving strategies and emerging options. PRIMO Annual Conference: Maui, HI
- 2/18 Between the motion and the act falls the shadow: the disparity between best evidence and actual clinical practice in cancer care. PRIMO Annual Conference: Maui, HI
- 2/18 Small cell lung cancer: nivolumab, monotherapy and combinations. IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA
- 7/18 This changes everything: Key developments in how oncology practice is evolving. Best of ASCO Miami, Miami, FL
- 8/18 Stage III NSCLC: Where are we now? Medical Oncology Group of Australia Annual Society Meeting, Adelaide, South Australia
- 8/18 Biomarkers in immunotherapy for lung cancer: PD-L1, TMB, and beyond. Medical Oncology Group of Australia Annual Society Meeting, Adelaide, South Australia
- 8/18 ASCO 2018 highlights in metastatic NSCLC. 6th International Conference on Advances in Hematology and Oncology, Coeur d'Alene, ID
- 9/18 The great oligometastatic debate: locally ablative therapies should be standard treatment for patients with oligometastases. World Conference on Lung Cancer, Toronto, ON, Canada
- 10/18 Tumor mutational burden as a clinical tool for advanced NSCLC. Master Class in Lung and Head/Neck Cancer, Dallas, TX
- 10/18 Current standards of care for managing advanced squamous NSCLC. Master Class in Lung and Head/Neck Cancer, Dallas, TX
- 10/18 Emerging options in managing CNS disease in NSCLC: The expanding role of systemic therapies. Personalized Therapies in Lung Cancer, San Francisco, CA

- 11/18 Optimizing treatment strategies in the management of advanced non-small cell lung cancer (NSCLC): Individualized therapy for improved patient outcomes. Fall Managed Care Forum, Las Vegas, NV
- 2/19 TAK-788. IASLC Targeted Therapies in Lung Cancer Conference, Santa Monica, CA.
- 2/19 Case-based peer perspectives on immunotherapy in lung cancer. Santa Monica, CA
- 5/19 How new technologies impact the dissemination of information to health professionals. Avançons 3.0, Nice, France
- 5/19 US perspective on how, when, & which immunotherapy in advanced NSCLC. Avançons 3.0, Nice, France
- 5/19 Sequencing of targeted therapies. A US perspective. Avançons 3.0, Nice, France
- 5/19 Weighing the evidence: How to read molecular profiling reports. ASCO Educational Session, Chicago, IL
- 7/19 How new technologies impact the dissemination of information to health professionals. ASCO Direct Highlights, Miami, FL
- 7/19 First line EGFR-TKI therapy for patients with metastatic EGFR mutation-positive NSCLC. Fullerton, CA
- 9/19 Chemotherapy, immunotherapy, targeted therapy: can we improve outcomes by Optimizing sequence? IASLC World Conference on Lung Cancer, Barcelona, Spain
- 9/19 Case-based peer perspectives on metastatic NSCLC, no drivers. Pasadena, CA
- 10/19 Transforming the treatment of NSCLC. Grand Rounds, University Hospitals Cleveland Medical Center, Cleveland, OH
- 2/20 What have we learned in 2019? Combination treatments for patients with advanced or metastatic NSCLC. International webinar to China.
- 2/20 What have we learned in 2019? Combination treatments for patients with advanced or metastatic NSCLC. International webinar to Singapore and other sites in Asia
- 3/20 OncLive International COVID-19 Symposium. Managing lung cancer patients through the COVID-19 pandemic. Online international symposium.
- 4/20 OncLive International COVID-19 Symposium. Managing lung cancer patients through the COVID-19 pandemic. Online international symposium
- 4/20 Telemedicine as a new management option. COVID-19 Virtual Town Hall. Online international symposium
- 5/20 Tailoring targeted therapies: what TKI is suitable for which patients? International Lung Cancer Summit (Geneva, changed to virtual international conference)
- 5/20 OncLive International COVID-19 Symposium. Managing lung cancer patients through the COVID-19 pandemic. Online international symposium
- 7/20 ADAURA – the debate. Oncoviews. Geneva, Switzerland (virtual)
- 9/20 ADAURA: a definitive answer to the wrong question. Toronto, ON, Canada (virtual)
- 10/20 Management of stage I-III NSCLC. City of Hope medical oncology fellowship education series (virtual)
- 11/20 Conversations in Oncology: Immunotherapy trials in early stage lung cancer. Expert opinion on Recent updates. Practice Point Communications (virtual)
- 2/21 Caring for patients with cancer through telehealth in the era of COVID-19 and beyond. 18th Annual Winter Lung Cancer Conference (virtual)
- 5/21 AJMC Oncology Value Coalition Webinar: Bringing Precision Medicine Solutions to the Cancer Journey. virtual)
- 7/21 Telemedicine and the Emerging Challenges of Cancer Care Deliver: The Right Drug in the Right Patient at the Right Time, *and in the Right Place*. ASCO Direct Highlights Miami (virtual).
- 7/21 Highlights in Non-Small Cell Lung Cancer. ASCO Direct Highlights. Seattle, WA.
- 8/21 Telemedicine in Cancer in the Age of COVID. California Cancer Consortium, Pasadena, CA.
- 8/21 Bringing Precision Medicine Solutions to Cancer. Northrop Grumman Symposium, virtual.
- 9/21 What evidence level is enough for approval and reimbursement of novel cancer drugs? Lessons from lung cancer. World Conference on Lung Cancer 2021, virtual.

- 9/21 A novel program offering remote, asynchronous subspecialist input in thoracic oncology: early experience during pandemic. World Conference on Lung Cancer 2021, virtual.
- 10/21 Tumor Sequencing for Detection of Molecular Abnormalities. Binayara Foundation 2021 Precision Oncology Summit, Salt Lake City, UT.
- 6/22 Targeted Therapies in Lung Cancer, ASCO 2022 Direct Highlights, Seattle, WA
- 6/22 The Evolution of Management of Unresectable Stage III NSCLC, New Orleans Summer Cancer Meeting, New Orleans, LA
- 7/22 Pros and Cons of Telemedicine in Cancer Care Today, ASCO Direct Highlights, Miami, FL
- 8/22 Telemedicine in 2021: Pros and Cons, World Conference on Lung Cancer, Vienna, Austria
- 7/23 Converting from Inside the Red Zone: Translating Molecular Testing Results to Optimal Treatment. Best of ASCO Miami, Miami, FL
- 7/23 Telemedicine in Oncology, New Orleans Summer Cancer Meeting, New Orleans, LA

X. GRANTS

No grant support at this time.

XI. MEDIA/OTHER COMMENTARY

Medscape commentary pieces

- 11/08 Trying to define the right subgroup for cetuximab in NSCLC: EGFR FISH and K-RAS testing
- 11/08 Is improvement in progression-free survival without overall survival benefit enough in lung cancer?
- 12/08 Bringing gefitinib back to the US market? The argument that convinced me
- 12/08 The MARVEL trial: will it live up to its name?
- 12/08 How negative can a positive trial be? How little efficacy can we possibly accept in lung cancer?
- 12/08 Could a four-drug palliative NSCLC regimen really fly?
- 12/08 The adjuvant chemo regimen of choice for resected NSCLC
- 12/08 Does consolidation chemo after chemo/radiation in stage III NSCLC add something other than toxicity?
- 12/08 Patient ratings for physicians: give the people what they want?
- 1/09 Buying our own pens: we don't need the meaningless distraction
- 1/09 Can development of a rash on cetuximab predict who will benefit?
- 1/09 The path CR issue: great result or over-treatment for locally advanced NSCLC?
- 1/09 E-patients: oncology practice in the internet era
- 1/09 Bronchioloalveolar carcinoma (BAC): Top problems with how we manage it (part 1/2)
- 2/09 Bronchioloalveolar carcinoma (BAC): Top problems with how we manage it (part 2/2)
- 2/09 The shifting ground in first line advanced NSCLC: a poll of the experts
- 2/09 Commercial serum test to predict response to EGFR TKI therapy coming
- 2/09 Institutional restrictions on expensive anti-cancer agents
- 3/09 The hardest part of the job
- 3/09 Early impressions with the Biodesix Veristrat test of survival with an EGFR TKI
- 3/09 Asking the experts: case of newly diagnosed metastatic NSCLC, squamous cell histology
- 3/09 Is ERCC-1 ready for prime time in NSCLC management?
- 4/09 The excruciating slowness of clinical trials
- 4/09 EGFR mutations and tumor heterogeneity
- 4/09 "Maintenance" chemotherapy vs. a well-deserved break from treatment for advanced NSCLC
- 5/09 Long-term survivors with advanced lung cancer: how much progress are we really making?
- 5/09 Is there a best time and way to discuss prognosis?
- 5/09 ASCO News: tweets from the front
- 5/09 Hazard ratios as a method of obfuscation
- 6/09 Back from a subdued ASCO
- 6/09 The benefit with vandetinib (Zactima): damning with faint praise
- 6/09 Pre-op vs. post-op chemo showdown in early stage NSCLC: the NATCH trial

6/09 Treating the very elderly: moving beyond the feel-good myth that age doesn't matter
 7/09 K-RAS mutations and experts offering the word from God
 7/09 EML4-ALK: the most important marker in lung cancer you probably haven't heard about
 7/09 SATURN shows survival benefit: will maintenance therapy reach a tipping point?
 7/09 Effective vs. cost-effective medicines in lung cancer and other onc settings: facing tough decisions
 8/09 Is "maintenance therapy" now a paradigm shift?
 8/09 Saying goodbye to BAC: it's now adenocarcinoma *in situ*
 8/09 Come to sunny Seattle for a great interactive lung cancer program
 8/09 Current status of EGFR & K-RAS mutation testing for NSCLC: my perspective & practice
 8/09 Struggling with conflicting data: my current approach with bevacizumab
 8/09 Who should receive bevacizumab? Growing experience expands clinic comfort zone
 9/09 A disturbing case of needle track seeding
 9/09 The oldest debate in lung cancer: cisplatin vs. carboplatin, part 1 – advanced NSCLC
 9/09 Underachieving by settling for less? cisplatin vs. carboplatin in early stage NSCLC
 10/09 Chemotherapy regimens for locally advanced NSCLC: the need for systemic efficacy
 10/09 Consolidation chemo after chemo/radiation for stage III NSCLC: trusting the heart over the head?
 10/09 The data vs. marketing gap
 10/09 Where does irinotecan fit into SCLC management in the US today?
 11/09 What EGFR mutation testing does and does not tell us
 11/09 Adding bevacizumab in SCLC: another case of "can we?" vs. "should we?"
 11/09 Promise vs. reality of molecular testing in lung cancer
 11/09 Sensationalism of cancer coverage in the mass media
 12/09 Maintenance therapy for advanced NSCLC: not accepted as the standard of care
 12/09 Localized therapy in metastatic NSCLC: not just for the "precocious" metastasis?
 12/09 Not as simple as "ever-smoker" vs. "never-smoker": smoking history as a continuous variable
 12/09 Do you use molecular markers in lung cancer? if so, how?
 1/10 Continuing treatment through (slowly) progressing disease?
 1/10 Is there an optimal time to discuss prognosis and hospice with patients with terminal cancer?
 1/10 An effective treatment for (some patients with) leptomeningeal carcinomatosis from lung cancer?
 2/10 Long-term follow-up of the IALT study: reason to question adjuvant chemotherapy?
 2/10 When bad trials happen to good people: assigning patients with an EGFR mutation to first line chemo
 2/10 Surgery for small cell lung cancer: revisiting the question
 3/10 What happens to ground glass opacities left behind after resection of a BAC lesion? often nothing.
 3/10 The dilemma of poorly differentiated NSCLC, "not otherwise specified"
 3/10 What molecular markers to order in non-small cell lung cancer? it's a murky mess!
 4/10 My practice for ordering molecular markers for targeted therapy: a proposal for community oncology
 4/10 Molecular markers for chemotherapy efficacy in NSCLC: different thresholds for different situations
 4/10 Insights from the BATTLE trial
 5/10 What is the value of attending the live ASCO meeting?
 5/10 ASCO preview: the significance of the TORCH trial
 6/10 What would you do if it were your wife?
 6/10 Can we overcome the hypocrisy of physician (and institution)-pharma interaction?
 7/10 Changing practice in NSCLC: new research highlights value of early molecular testing
 7/10 Should EGFR inhibitor therapy be continued after progression?
 8/10 Hope, false hope, and marketing
 8/10 Avastin in breast cancer: should different cancers operate by different rules?
 9/10 Should we recommend an EGFR inhibitor as adjuvant therapy to patients with an EGFR mutation?
 10/10 Is progress in advanced NSCLC going to slow because trials are getting harder to run?
 10/10 Patient-facilitated research in the new era of medical information delivered by pull, not push
 10/10 MetMab looking promising for about half of patients with advanced NSCLC
 11/10 Lung cancer now on the short list of cancer for which screening offers proven survival benefit

- 11/10 Dartmouth Atlas Project reflects our (suboptimal) management of end of life care for cancer patients
- 12/10 Denosumab approved for patients with solid tumors: worth the cost vs. zoledronic acid?
- 12/10 What lung cancer staging doesn't tell us
- 1/11 Can an aspirin a day keep cancer away?
- 1/11 First line EGFR TKI vs chemo for EGFR mutation-positive advanced NSCLC: consistent themes
- 1/11 Hormonal status in women and risk of death from lung cancer: tamoxifen as lung cancer therapy?
- 2/11 A new classification of lung adenocarcinoma: the way of the future or historical footnote?
- 2/11 Acquired resistance/modest progression after a great response to EGFR TKI therapy: what to do?
- 3/11 Practical tip: pemetrexed may be particularly effective for ALK-positive NSCLC
- 3/11 Molecular testing opportunism
- 4/11 Should molecular marker testing be broadly pursued in advanced NSCLC? no evidence supports it.
- 5/11 Striving to balance the risks of undertreatment vs. overtreatment of stage III NSCLC
- 5/11 NEJM piece suggests 5 key ways oncologists cancer reduce costs of care but not survival
- 6/11 Dream big: 5 recommended shifts in attitude and societal priorities for improving cancer care
- 7/11 Denosumab vs. zoledronate trial shows significant survival benefit for d'mab in lung cancer
- 8/11 Variability of tumor measurements in chest CTs: radiographic vs. clinically significant progression
- 9/11 New ASCO guidelines on stage IV NSCLC contrast NCCN, call molecular testing investigational
- 10/11 Surprising news from RTOG: more (radiation) not better for stage III NSCLC
- 11/11 When patients are teaching you: the evolution of the doctor/patient relationship
- 12/11 The PARAMOUNT trial of continuation maintenance therapy: what conclusions can we really make?
- 12/11 Revisiting the tenet that benefit of chemotherapy for advanced NSCLC is exhausted after four cycles
- 1/12 Whose job is it to consider the cost of cancer treatment?
- 4/12 Could we go from pooled, collaborative art projects to a poor man's cooperative group?
- 5/12 Should we continue targeted therapies in NSCLC after acquired resistance?
- 7/12 My top ten lung cancer highlights from ASCO: the view from 20,000 feet
- 7/12 Breaking the KRAS impasse, if we can overcome toxicity
- 8/12 Is single agent chemo under-treating marginal performance status NSCLC patients?
- 10/12 Afatinib for EGFR mutation-positive advanced NSCLC: is it better than what we already have?
- 10/12 Chemo vs. erlotinib for EGFR wild type: does the tailor trial really fit?
- 11/12 Should development of rash be a decision making point in continuing erlotinib?
- 12/12 What does survival benefit in the PARAMOUNT trial of continuation maintenance therapy mean?
- 5/17 New standards of care for EGFR mutation-positive advanced NSCLC
- 5/17 Expert panel: should genomic testing be broadly used in cancer?
- 7/17 Adjuvant TKI therapy for early-stage EGFR mutation-positive NSCLC
- 8/17 Combining immunotherapy agents in NSCLC: is MYSTIC a misstep?
- 9/17 Jack West, MD: top five lung cancer abstracts at ESMO 2017
- 11/17 Immunotherapy for lung cancers: first-line and beyond
- 11/17 ESMO's practice-changing lung cancer data: three experts discuss
- 11/17 Tumor mutational burden as an immunotherapy predictive biomarker
- 12/17 "Stepping back from the hype": a critical look at NGS
- 1/18 Top 5 practice-changing developments in lung cancer in 2017
- 2/18 It's time to renew our vows with evidence-based medicine
- 3/18 "Reinventing healthcare" without the people who care for patients
- 4/18 Interpreting KEYNOTE-189 and CheckMate-227 for clinical practice
- 5/18 Is this new immunotherapy biomarker really "ready for primetime"?
- 5/18 PFS is a shortcut, not a destination
- 5/18 KEYNOTE-189: chemo + immunotherapy now viable for PD-L1 low NSCLC
- 5/18 Trial "desperately needed" to sequence immunotherapy and chemo in lung cancer
- 5/18 Time to "rethink" immunotherapy for molecularly driven NSCLC
- 5/18 Dealing with data overload in oncology
- 5/18 Which patients with CNS metastases can avoid radiation?

6/18 When online information is the “third party in the exam room”
 6/18 Tumor mutation burden as biomarker: all-systems-go or too early?
 6/18 ASCO data established chemo-IO as mainstay frontline for NSCLC
 6/18 The best ways to dispel patients’ “cancer myths” in clinical practice
 6/18 In NSCLC, immunotherapy evolving to become first-line treatment
 7/18 Does immunotherapy have a role in EGFR-mutant lung cancer?
 8/18 Is upfront combo therapy better than the sum of its parts?
 9/18 Jack West: why CMS’ step therapy decision is so dangerous
 10/18 How the 2018 WCLC data change lung cancer practice
 11/18 At ESMO, new data on managing long-term immunotherapy responders
 12/18 You don’t need 800 cable channels (or tumor genetic mutations)
 2/19 Is it timing or access? How clinical trials game the system
 3/19 Linking community and academic oncologists: creating a new model
 4/19 Should we be doing molecular testing at the time of acquired resistance?
 5/19 “How could we fail so miserably?”
 6/19 ASCO: ain’t nothing like the real thing, baby
 6/19 “Mind-boggling” IO data, plus new combos, targets for NSCLC
 6/19 Notion of academic and community oncology “tribes” needs to end
 6/19 New targets in lung cancer shape treatment options
 8/19 Time to rethink treating brain metastases in NSCLC?
 11/19 “Open Notes”: too much transparency with patients?
 1/20 Overcoming territoriality in palliative cancer care
 1/20 Top 5 advances in lung cancer immunotherapy over the past decade
 3/20 Italian oncologist’s cautionary advice on COVID-19 for US centers
 3/20 5 key targeted therapy advances for lung cancer
 4/20 Executing molecular testing across a health care system
 5/20 Has “patient-centeredness” gone too far?
 6/20 ADAURA trial: breaking through the hype
 6/20 We can’t afford to be “cost-agnostic” with our cancer patients
 8/20 Why are oncologists deviating from best evidence in NSCLC?
 9/20 5 reasons why medical meetings will never be the same
 10/20 Oncology is not immune from online “confirmation bias”
 12/20 Happy days in oncology: more applause, less rigor?
 1/21 Identity onco-politics is impairing our objectivity
 2/21 Sifting through the wreckage of 2020: 5 things worth salvaging
 4/21 The dangers of incentivizing mediocrity with “me-too” drugs
 6/21 Telemedicine beyond the pandemic
 8/21 From cancer to COVID: is there a fix for willful medical ignorance?
 9/21 Oncologists still failing “woefully” at molecular testing in lung cancer
 9/21 Can telemedicine survive? 5 ways to invest in the future of virtual care
 10/21 Which cancer treatment is best? Selecting the right tool for the job
 10/21 When phase 3 data can’t guide oncology decision-making
 11/21 Too soon to utter the word “cure” in advanced lung cancer?
 1/22 Swinging for the fences: curing NSCLC
 3/22 Is a PFS benefit alone really worth \$10,000 a month?
 4/22 Twitter polls: tapping into the wisdom of crowds
 6/22 Why is adhering to standard of care so elusive?
 7/22 Live meetings: is the juice still worth the squeeze?
 10/22 We are rebranding suboptimal care as real world practice
 11/22 How would you treat your spouse? Practical, but not hard evidence
 11/22 Discerning bias in cancer news
 11/22 Discontinuing immunotherapy: Half empty or half full?

- 12/22 The fix we need to break the impasse in precision oncology
- 2/23 Local therapies show promise for metastatic lung cancer
- 3/23 When practice-changing results don't change practice
- 5/23 The upside of rejection
- 6/23 Did an unfair system help ADAURA win on overall survival?
- 9/23 Unless it improves survival, more is not better

JAMA Oncology Audio Podcasts (host)

- 2/15 Hereditary diffuse gastric cancer syndrome, with guest David Huntsman, MD
- 3/15 21-gene recurrence score assay for breast cancer, with guest Michaela A Dinan, PhD
- 4/15 Chemoresistance after consumption of fish and fish oil, with guest Emile E. Voest, MD, PhD
- 5/15 The global burden of cancer 2013, with guest Christopher Murray, DPhil, MD
- 6/15 Obesity and postmenopausal invasive breast cancer, with guest Maian L. Neuhouwer, RD
- 7/15 Trends in advance care planning in patients with cancer, with guests Amol K. Narang, MD & Michael J. Fisch, MD
- 8/15 Differences in the acute toxic effects of breast radiotherapy, with guests Reshma Jagsi, MD, DPhil & Benjamin D. Smith, MD
- 9/15 Agent Orange exposure and monoclonal gammopathy, with guests Ola Landgren, MD, PhD, & Nikhil C. Munshi, MD
- 10/15 Breast tumor characteristics and biennial vs. annual mammography, with guest Diana L. Miglioretti, PhD
- 11/15 Erlotinib and risk of oral cancer, with guests William N. William Jr, MD & Scott Lippman, MD
- 12/15 Delayed initiation of chemotherapy and breast cancer, with guests Mariana Chavez-MacGregor & Richard J. Bleicher, MD
- 1/16 Molecular profiling in pediatric tumors, with guests Katherine A. Janeway, MD, MSc and D. Williams Parsons, MD, PhD
- 2/16 BRCA1 and BRCA2 mutation testing in young women with breast cancer, with guest Ann H. Partridge, MD, MPH
- 3/16 Effect of long-term use of aspirin on the risk for cancer, interview with Andrew T. Chan, MD, MPH
- 3/16 Prostate-specific antigen screening and selective treatment, with guests Ruth Etzioni, PhD & Andrew J. Vickers, PhD
- 4/16 Neratinib vs. trastuzumab for untreated metastatic ERBB2-positive breast cancer, with guests Ahmad Awada, MD, PhD, and Mark Pegram, MD
- 5/16 Lifestyle associations with US cancer incidence and mortality, with guest Mingyang Song, MD, ScD
- 6/16 Physiologic frailty in hematopoietic cell transplantation patients, with guest Smita Bhatia, MD, MPH
- 7/16 Outcomes for biomarker-based treatment strategies in refractory malignant neoplasms, with guest Razelle Kurzrock, MD
- 8/16 ESR1 mutations in metastatic breast cancer, with guest Sarat Chandarlapaty, MD, PhD
- 9/16 Prognostic factors for local control in breast cancer with boost vs. no boost, with guest Conny Vrieling, MD, PhD
- 10/16 Adjuvant endocrine therapy and risk of contralateral breast cancer, with guest Gretchen L. Gierach, PhD
- 10/16 Association between androgen deprivation therapy and risk of dementia, with guest Kevin T. Nead, MD, MPhil
- 11/16 Comparison of vaginal testosterone cream vs. estradiol vaginal ring, with guest Michelle E. Melisko, MD
- 12/16 Global burden of cancer 2015, with guest Christina Fitzmaurice, MD, MPH
- 1/17 Delayed adjuvant chemotherapy after lung cancer surgery, with guest Daniel Joseph Boffa, MD
- 2/17 Patient reporting of symptomatic adverse events in multicenter cancer trials, with guest Ethan M. Basch, MD, MSc
- 3/17 Birth outcomes among adolescent and young adult cancer survivors, with guest Hazel B. Nichols, PhD
- 4/17 Incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors, with guest Arvind Dasari, MD
- 7/17 Breast cancer due to non-BRCA1 and non-BRCA2 mutations in Ashkenazi Jewish Women, with guest Mary-Claire King

- 8/17 Prevalence of cancer in Li-Fraumeni Syndrome Cohort, with guest Sharon A. Savage, MD
- 8/17 Trends in adult cancer-related emergency department utilization, with guests Nonniekaye Shelburne, BSN, MS, & Demetrios Kyriacou
- 10/17 Prophylactic surgery for stage IV small intestinal neuroendocrine tumors, with guest Kosmas Daskalakis, MD
- 11/17 Critical lessons from high-value oncology practices, with guest Douglas W. Blayney, MD
- 12/17 Preoperative vs. postoperative CEA and colon cancer outcome, with guest Martin R. Weiser, MD
- 1/18 Dietary inflammatory potential and risk of colorectal cancer in men and women, with guests Fred K. Tabung, & Charles S. Fuchs, MD, MPH
- 2/18 Atezolizumab monotherapy for patients with metastatic urothelial cancer, with guest Daniel P. Petrylak, MD, PhD
- 3/18 Standard vs. dose-escalated radiotherapy in medium-risk prostate cancer, with guest Jeff Michalski, MD
- 4/18 Association of colon cancer survival with ACS guideline adherence, with guests Erin L. Van Blarigan, ScD & Jeffrey A. Meyerhardt, MD, MPH
- 5/18 Outcomes of multiple-gene sequencing after diagnosis of breast cancer, with guest Allison W. Kurian, MD, MSc
- 6/18 Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockage, with guest Aaron Goodman, MD
- 7/18 Cost-effectiveness and benefit-to-harm ratio of risk-stratified breast cancer screening, with guest Nora Pashayan, BSc, MSc, MSt, MD, PhD, FFPH
- 8/18 Maintenance treatment and survival in patients with myeloma, with guest Francesca Gay
- 9/18 Hyperprogressive disease in patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors, with guest Benjamin Besse, MD
- 10/18 Analgesic use and risk of ovarian cancer in the Nurses' Health Studies, with guests Mollie E. Barnard, ScD & Shelley Tworoger, PhD
- 11/18 Surgery vs. Radiotherapy in the management of Gleason score 9-10 prostate cancer and the risk of mortality, with guest Anthony D'Amico, MD, PhD
- 12/18 Association of body fat and risk of breast cancer in post-menopausal women with normal BMI, with guest Andrew J. Dannenberg, MD
- 1/19 Association of patient comorbidity conditions with cancer clinical trial participation, with guests Joseph M. Unger, PhD & Dawn Hershman, MD
- 2/19 Integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer, with guest David A. Palma, MD, PhD
- 3/19 The role of disease label in patient perceptions and treatment decisions in the setting of low-risk malignant neoplasms, with David Urbach
- 4/19 Single-fraction stereotactic vs. multifraction radiotherapy for pain relief in patients with nonspine bone metastases, with guest Quynh-Nhu Nguyen, MD
- 5/19 Prognostic potential of circulating tumor DNA measurement in nonmetastatic colorectal cancer, with guest Jeanne Tie
- 6/19 Evaluation of USPSTF lung cancer screening guidelines among African American adult smokers, with guest Melinda C. Aldrich
- 7/19 Five-year survival among patients with advanced skin-renal, and lung cancer treated with nivolumab, with guest Suzanne L. Topalian, MD
- 8/19 Women's representation among lead investigators of clinical trials in oncology, with guest Emma B. Holliday, MD
- 9/19 Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer, with guest David J. Pinato, MD
- 10/19 Cost-effectiveness of multigene testing for all patients with breast cancer, with guest Ranjit Manchanda, MD
- 12/19 The role of maintenance strategies in metastatic colorectal cancer, with guest Mohamad Bassam Sonbol, MD

- 12/19 Association between BMI and overall survival in advanced non-small cell lung cancer, with guest Ganessan Kichenadasse, MBBS, FRACP
- 1/20 Cost transparency for prostate cancer radiation therapy at National Cancer Institute-designated cancer centers, with guest Trevor J. Royce, MD, MS, MPH
- 2/20 HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer, with guest Nima Sharifi, MD
- 4/20 Durvalumab with or without tremelimumab vs. standard chemotherapy for metastatic NSCLC, with guest Naiyer A. Rizvi
- 4/20 Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer, with guest Charles Dolladille, MD, MSc
- 6/20 First-line radiosurgery for small cell lung cancer (FIRE-SCLC) brain metastases: an international multicenter analysis, with guest Chad G. Rusthoven, MD
- 6/20 Association of sedentary behavior with cancer mortality in middle-aged and older US adults, with guest Susan C. Gilchrist, MD MS
- 7/20 Presence of ctDNA and CTCs after chemotherapy and recurrence of triple-negative breast cancer, with Bryan P Schneider, MD and Milan Radovich, MD
- 8/20 Tailoring intensity of surveillance for prostate cancer based on prediction of risk stability, with Matthew R. Cooperberg, MD, MPH
- 9/20 Survival and adjuvant chemotherapy in early-stage NSCLC with vs. without clinicopathologic features, with Daniel J. Boffa, MD
- 10/20 Association of measurable residual disease with survival in patients with acute myeloid leukemia, with Farhad Ravandi, MD
- 11/20 Discontinuation of tyrosine kinase inhibitors for patients with chronic myeloid leukemia, with Ehab Atallah, MD
- 12/20 Osteonecrosis of the jaw in patients receiving zoledronic acid for bone metastases, with Catherine Van Poznak, MD
- 1/21 Virtual care across a tertiary care center during COVID-19, with Alejandro Berlin, MD, MSc
- 2/21 Anti-PD-1 immunotherapy in microsatellite-stable tumors with 10 or more mutations per megabase, with Luc GT Morris, MD, MSc
- 3/21 Chronic toxic effects following adjuvant anti-PD-1 therapy for high-risk resected melanoma, with Douglas B. Johnson, MD
- 4/21 Association between KRAS variant status and outcomes with first-line immune checkpoint-based therapy in patients with advanced NSCLC, with Charu Aggarwal, MD and Lova Sun, MD
- 5/21 Efficacy and safety of stereotactic radiosurgery for brainstem metastases, with David R. Raleigh MD, PhD, and William C. Chen, MD
- 6/21 Trastuzumab, pertuzumab, and docetaxel vs. trastuzumab emtansine in ERBB2-positive breast cancer, with Thomas Hatchek, MD, PhD
- 7/21 Neuronal autoantibodies and cognitive impairment in patients with lung cancer, with Carsten Finke, MD and Frederik Bartels, MD
- 8/21 Hypofractionated image-guided vs conventional radiotherapy for patients with NSCLC, with Puneeth Iyengar, MD, PhD
- 9/21 Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer, with Laura J. Esserman and W. Fraser Symmans, MD
- 10/21 Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitor treatment among patients aged 80 years or older with cancer: a multicenter international cohort study, with Abdul Rafah Naqash, MD & Caroline A Nebhan, MD, PhD
- 11/21 Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial, with Emmanouil Fokas, MD, DPhil
- 12/21 Final overall survival and molecular analysis in IMMotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma, with Robert J. Motzer, MD

- 1/22 Early readout on overall survival of patients with melanoma treated with immunotherapy, with Laurent Dercle, MD, PhD
- 2/22 Racial disparity in survival outcomes for early hormone receptor-positive breast cancer, with Ruth C. Carlos, MD and Gelareh Sadigh, MD
- 3/22 Guideline-concordant surgery and adjuvant chemotherapy among patients with early-stage lung cancer, with Kenneth L. Kehl, MD, MPH
- 4/22 Treatment de-escalation with radiotherapy vs. transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma, with David A. Palma, MD, PhD, and Anthony C. Nichols, MD
- 5/22 Association of 5-alpha reductase inhibitors with prostate cancer mortality, with Lars Björnebo, MSc and Anna Lantz, MD, PhD
- 6/22 High TMB in NSCLC and improved immune infiltration and improved clinical outcomes of PD-L1 blockade, with Mark Awad, MD, PhD
- 7/22 Global association of COVID-19 pandemic measures with cancer screening, with Paolo Boffetta, MD
- 8/22 Therapy and survival patterns in patients with stage 2/3 rectal cancer treated with trimodality therapy, with Hagen F. Kennecke, MD
- 10/22 Prostate-specific antigen screening rates and metastatic prostate cancer incidence in the VHA, with Brent S. Rose, MD
- 10/22 Association of immune-related adverse event management with survival in patients with advanced melanoma, with Olivier J. van Not, MD and Karijn P.M. Suijkerbuijk, MD, PhD
- 11/22 Association of DCVax-L with extension of survival among patients with glioblastoma, with Linda M. Liau, MD, PhD
- 12/22 Adjuvant chemotherapy in patients with pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy, with Marco Del Chiaro, MD, PhD
- 1/23 Adoption of innovative therapies across oncology practices, with Nancy L. Keating, MD, MPH
- 2/23 Association of a Mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma, with Laura A. Bolte, MSc, Geke A. Hospers, MD, PhD, & Rinse K. Weersma, MD, PhD
- 3/23 Pathologic complete response and clinical outcomes in soft tissue sarcoma, with Dian Wang, MD
- 4/23 Radiosurgery of spine metastasis – NRG/RTOG 0631 randomized controlled trial final results, with Samuel Ryu, MD
- 5/23 Oncolytic viral immunochemotherapy in patients with ovarian cancer, with Robert W. Holloway, MD and Sarfraz Ahmad, PhD
- 6/23 US cancer mortality trends among Hispanic populations from 1999 to 2020, with Sophia C. Kamran, MD
- 7/23 Integrated clinical-molecular classification of colorectal liver metastases, with Sean P. Pitroda, MD
- 8/23 A geospatial analysis of disparities in access to oncofertility services, with Kara N. Goldman, MD
- 9/23 Sentinel lymph node biopsy vs. no axillary procedure in small node-positive breast cancer, with Oresete Davide Gentilini, MD

International Association for the Study of Lung Cancer Official Podcast “Lung Cancer Considered” (host)

- 4/19 The evolution of small cell lung cancer, with Drs. Christine Hann & Stephen Liu
- 4/19 A conversation with IASLC President, Giorgio Scagliotti
- 5/19 A conversation with medical oncologist Joan Schiller
- 5/19 Blood-based testing and the evolution of lung cancer, with Dr. David Gandara
- 6/19 Medication for lung cancer treatment, with Dr. David Spigel
- 6/19 Radiation oncology and proton therapy, with Dr. Walter J. Curran
- 7/19 Lung cancer management and niche patients, with Dr. Corey Langer
- 7/19 State of mesothelioma treatment, with Dr. Anne Tsao
- 7/19 NGS testing and participation and funding in clinical trials, with Dr. Alexander Drilon
- 8/19 Highlights of the Journal of Thoracic Oncology, with Alex Adjei
- 8/19 ASCO wrap-up, with Dr. Christine Lovly
- 9/19 Lung cancer trends in Europe, with Dr. Rami Porta

- 9/19 Lung cancer trends in Australia, with Dr. Ben Solomon
- 10/19 IASLC 2019 WCLC highlights, with Dr. Tony Mok
- 10/19 Women in lung cancer, with Drs. Heather Wakelee & Corinne Faivre-Finn
- 11/19 Women in lung cancer – patient advocacy, with Montessa Lee & Janet Freeman-Daily
- 11/19 Lung cancer research trends in France, with Dr. Benjamin Besse
- 12/19 CT lung cancer screening for first responders, with Dr. Vershalee Shukla
- 12/19 The formation of the Lung Ambition Alliance, with Patrick Connor & Maureen Rigney
- 4/20 COVID-19 JTO report, with Dr. Shu-Yuan Xiao
- 4/20 JTO study on smoking cessation impact in lung cancer screening, with Dr. Rafael Meza
- 6/20 IASLC radiation oncology and COVID-19 webinar recap, with Dr. Corinne Faiver-Finn
- 7/20 The pros and cons of telemedicine in medical oncology, with Drs. Mary Jo Fidler and Sandip Patel
- 7/20 ADAURA: a lively debate among key voices, with Drs. Chandra Belani (host), Nate Pennell, & myself
- 9/20 Digital connections as an educational tool, with Dr. Sanjay Mukhopadhyay
- 10/20 Immunotherapy for Patients with Lung Cancer, with Dr. Matt Hellman
- 11/20 Lung Cancer Management and Clinical Research in India, with Dr. Vanita Noronha

OncLive Content (print or video)

- 5/10 E-Patients. The genie is out of the bottle (print)
- 6/10 Wests Points: evolving issues with ALK rearrangements (print)
- 8/10 Dr. West talks about the escalating cost of cancer care (video)
- 6/11 Dr. West discusses crizotinib in ALK-NSCLC trial results (video)
- 6/11 Dr. West on ALK-NSCLC crizotinib survival benefit (video)
- 7/11 Dr. West on NSCLC afatinib and cetuximab combination (video)
- 7/11 Dr. West on the gefitinib advanced NSCLC trial (video)
- 7/11 Dr. West explains the pemetrexed clinical trial (video)
- 7/11 Dr. West on 4 important upcoming clinical trial results (video)
- 8/11 Dr. West discusses anticipated future clinical trials (video)
- 7/14 Nab-paclitaxel in non-small cell lung cancer (print)
- 7/14 Maintenance nab-paclitaxel in squamous NSCLC (video)
- 8/14 AZD9291 and rociletinib in T790M-mutant NSCLC (video)
- 10/14 Efficacy of next generation ALK inhibitors (video)
- 11/14 Nivolumab in non-small cell lung cancer (video)
- 11/14 Role of maintenance therapy in NSCLC (video)
- 12/14 Emerging therapies in non-small cell lung cancer (video)
- 1/15 West describes strategies for personalizing NSCLC therapy (print)
- 4/16 Twitter becomes forum for Opdivo coverage dispute (print)
- 8/16 Dr. West on advancements for patients with T790M-mutant NSCLC
- 11/16 Emerging data could rearrange frontline EGFR TKIs in NSCLC (print)
- 11/16 Dr. West on considering factors for EGFR TKIs in NSCLC (video)
- 2/17 Expert explains efforts to optimize EGFR TKIs in NSCLC (print)
- 5/17 Dr. West on FDA approval of brigatinib in ALK+ NSCLC (video)
- 5/17 Dr. West on FDA approval of frontline ceritinib for ALK+ NSCLC (video)
- 5/17 ASCO 2017: oncology leaders pick their top abstracts (print)
- 6/17 Dr. West on emerging changes in the field of EGFR-mutant NSCLC (video)
- 9/17 Dr. West on the significance of the PACIFIC trial in NSCLC (video)
- 9/17 Dr. West on lurbinectedin in SCLC (video)
- 11/17 Dr. West on FDA approval of frontline alectinib in ALK+ NSCLC (video)
- 11/17 Treating advanced non-driver lung adenocarcinoma (print)
- 1/18 Dr. West on FDA approval of afatinib in NSCLC with rare EGFR mutations (video)
- 1/18 Dr. West discusses chemotherapy without driver mutations in NSCLC (video)
- 1/18 FDA expands afatinib's approval for lung cancer (print)
- 4/18 Dr. West on FDA approval of frontline osimertinib in EGFR+ NSCLC (video)

- 4/18 Durvalumab improves survival in stage III NSCLC (print)
- 5/18 ASCO 2018: top oncologists select key, practice-changing abstracts (print)
- 6/18 Practice changes for use of immunotherapy in NSCLC (video)
- 7/18 Dr. West discusses latest immunotherapy findings in lung cancer (video)
- 7/18 Atezolizumab regimen extends PFS in frontline non-squamous NSCLC (print)
- 7/18 KEYNOTE trial data: pembrolizumab's role in NSCLC (video)
- 7/18 Actual use of pembrolizumab and chemotherapy in NSCLC (video)
- 7/18 CheckMate-227: testing ipilimumab/nivolumab in NSCLC (video)
- 7/18 Impower150: implications for the treatment of NSCLC (video)
- 7/18 Important data in the squamous NSCLC population (video)
- 7/18 Tumor mutational burden in NSCLC: should it be routine?
- 7/18 Impact of data on the real-life treatment of NSCLC
- 7/18 Optimizing immunotherapy in the NSCLC treatment paradigm
- 7/18 Using immunotherapy beyond progression in NSCLC
- 7/18 Practice changes for use of immunotherapy in NSCLC: Q&A
- 9/18 NSCLC findings support upfront immunotherapy (print)
- 11/18 Dr. West on FDA approval of lorlatinib in ALK+ NSCLC (video)
- 1/19 CRT in locally advanced NSCLC (video)
- 1/19 Chemotherapy considerations in locally advanced NSCLC (video)
- 1/19 Durvalumab after CRT in locally advanced NSCLC (video)
- 1/19 EGFR and PD-L1 testing in locally advanced NSCLC (video)
- 1/19 Surgery and locally advanced NSCLC (video)
- 1/19 Chemo + I-O in frontline mNSCLC: PD-L1 TPS 1%-49% (video)
- 1/19 Chemo + I-O in frontline mNSCLC: PD-L1 TPS ≥50% (video)
- 1/19 Combinations with novel agents for metastatic NSCLC (video)
- 2/19 TMB with novel agents for metastatic NSCLC (video)
- 2/19 NSCLC: treating progression after chemo and I-O (video)
- 2/19 Frontline treatment for EGFR+ NSCLC (video)
- 2/19 Treatment of EGFR+ NSCLC after osimertinib (video)
- 2/19 Systemic therapy vs. radiotherapy for small brain mets (video)
- 2/19 Treating newly diagnosed ALK+ NSCLC (video)
- 2/19 Sequencing therapy in ALK+ NSCLC (video)
- 3/20 Coronavirus: what oncologists are telling their patients (print)
- 4/20 Weekly webinar series part 1: managing lung cancer patients through the COVID-19 pandemic (video)
- 4/20 Weekly webinar series part 2: managing lung cancer patients through the COVID-19 pandemic (video)
- 4/20 Weekly webinar series part 3: managing lung cancer patients through the COVID-19 pandemic (video)
- 4/20 Weekly webinar series part 4: managing lung cancer patients through the COVID-19 pandemic (video)
- 5/20 Continued webinar series part 5: managing lung cancer patients through the COVID-19 pandemic (video)
- 5/20 Continued webinar series part 6: managing lung cancer patients through the COVID-19 pandemic (video)
- 1/21 Dr. West on the use of nivolumab/ipilimumab in metastatic NSCLC

Targeted Oncology Content (print or video)

- 11/14 Strategies for precision medicine in NSCLC: a Q&A with Howard (Jack) West
- 10/15 Metastatic NSCLC with Corey J. Langer, MD, David Spigel, MD, Denise O'Dea, NP, and Jack West, MD: Case 1 (print and video)

- 10/15 Metastatic NSCLC with Corey J. Langer, MD, David Spigel, MD, Denise O'Dea, NP, and Jack West, MD: Case 2 (print and video)
- 6/16 Emerging agents for T790M-mutant patients with NSCLC (video)
- 11/16 Erlotinib plus bevacizumab in EGFR-mutant NSCLC (print and video)
- 1/18 Treating advanced lung cancer in patients without driver mutations (video)
- 7/18 Choosing between atezolizumab and pembrolizumab in lung cancer (print and video)
- 8/18 Data from the PACIFIC trial have changed the management of stage III NSCLC, observes West (print)
- 5/19 West discusses treatment strategies for squamous and nonsquamous NSCLC in 2 case scenarios (print)
- 4/20 Telemedicine takes the lead in cancer care strategy during the COVID-19 outbreak (print)

Beacon Medical Interchange content (video or audio) – primary presenter or host for all

- Importing immunotherapy into the curative setting for NSCLC: the potential implications of the PACIFIC Trial (8/17) (video)
- Early returns on the FLAURA trial: should osimertinib be a first line agent in EGFR mutation-positive NSCLC? (8/17) (video)
- Are two immunotherapy agents better than one? Will the MYSTIC trial prove to be a mistake? (8/17) (video)
- Better communication leads to better outcomes for cancer patients. (9/17) (video)
- Is there still a value in testing for PD-L1 expression in advanced NSCLC today? (9/17) (video)
- Immunotherapy in stage III NSCLC: the practice-changing results of the PACIFIC trial usher in a new standard (9/17) (video)
- The FLAURA trial: practice changing results for patients with EGFR mutation-positive NSCLC (9/17) (video)
- Do patients with advanced NSCLC doing well on an immune checkpoint inhibitor reach a point of diminishing returns after a fixed duration of treatment? (9/17) (video)
- Chemo-immunotherapy data increasingly compelling with additional follow-up (9/17) (video)
- How should we monitor patients after potentially curative surgery for lung cancer? Some actual evidence, at long last (9/17) (video)
- Tumor mutational burden in small cell lung cancer: a valuable biomarker for immunotherapy? (10/17) (video)
- Hyper-progressive disease on immunotherapy in advanced NSCLC (10/17) (video)
- Research question or standard of care: the barriers to broad adoption in cancer care (10/17) (video)
- Will immunotherapy shift the balance of treatment for borderline resectable stage III NSCLC away from surgery? (11/17) (video)
- Are the PD-1/PD-L1 immune checkpoint inhibitors completely interchangeable in lung cancer management? (11/17) (video)
- Dacomitinib: dark horse EGFR TKI charges into a crowded first line setting for EGFR mutation-positive advanced NSCLC (11/17) (video)
- Should osimertinib become first line treatment of choice for EGFR mutation-positive advanced NSCLC, or should it be saved for later? (12/17) (video)
- New target and treatment in advanced NSCLC: dabrafenib/trametinib for BRAF V600E mutation-positive NSCLC (12/17) (video)
- Genomic sequencing for all solid tumors: where will this lead us? (12/17) (video)
- Atezolizumab in first line NSCLC: early clinical results from the Impower150 trial (12/17) (video)
- T effector gene signature on Impower150: is there a better biomarker than PD-L1 for immunotherapy (12/17) (video)
- Chemo-immunotherapy in non-squamous NSCLC: Has the KEYNOTE-189 trial defined a clear standard of care? (1/18) (video)
- A new treatment option for uncommon EGFR mutations (1/18) (video)
- Durvalumab (Imfinzi) FDA approved for stage III NSCLC: should it become standard of care without overall survival benefit demonstrated? (2/18) (video)

Is durvalumab (Imfinzi) in stage III NSCLC curing patients or just treating metastatic disease earlier?
 Importance of overall survival and implications for duration of treatment (2/18) (video)

Chemo-immunotherapy in advanced squamous NSCLC? What is the impact of Impower131? (4/18) (video)

Is immunotherapy ineffective in patients with driver mutation-positive advanced NSCLC? Time to walk that back (4/18) (video)

New insights on acquired resistance to immune checkpoint inhibitors for NSCLC: implications for treatment options (4/18) (video)

Is chemotherapy more effective after prior immunotherapy? (4/18) (video)

KEYNOTE-189: key summary of a practice-changing trial in advanced non-squamous NSCLC (4/18) (video)

KEYNOTE-189: clinical implications in patients with advanced non-squamous NSCLC and high ($\geq 50\%$) tumor PD-L1 expression (4/18) (video)

KEYNOTE-189: clinical implications in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 expression (5/18) (video)

KEYNOTE-189: clinical implications in patients with advanced non-squamous NSCLC and negative ($< 1\%$) tumor PD-L1 expression (5/18) (video)

Nivolumab/ipilimumab vs. chemo in high TMB advanced NSCLC: key results from CheckMate-227 (5/18) (video)

Are tumor mutation burden and nivolumab/ipilimumab ready for clinical use? Insights from CheckMate-227 (5/18) (video)

My top 5 ASCO 2018 abstracts in advanced NSCLC (5/18) (video)

My top 5 ASCO 2018 abstracts in stage I-III NSCLC, small cell lung cancer, & mesothelioma. (5/18) (video)

KEYNOTE-042: should pembrolizumab replace chemo for a broader population of patients with advanced NSCLC? (6/18) (video)

KEYNOTE-407: practice-changing positive trial for advanced squamous NSCLC (6/18) (video)

Is nivo-ipi the treatment of choice for patients with advanced NSCLC, tumor PD-L1 $< 1\%$, & high TMB? New data from CheckMate-227 (6/18) (video)

Impower131: what is the role for the carbo/nab-paclitaxel/atezolizumab combination in advanced squamous NSCLC? (6/18) (video)

Small trial shows big risks of giving first line pembrolizumab to EGFR mutation-positive patients, even with high tumor PD-L1 expression (6/18) (video)

The erlotinib/bevacizumab combination in EGFR mutation-positive advanced NSCLC: is progression-free survival without overall survival benefit enough? (7/18) (video)

Is the survival benefit from dacomitinib on the ARCHER-1050 trial enough to make it a contender as first line treatment for EGFR mutation-positive NSCLC today? (7/18) (video)

Is chemo the key to the best combination for EGFR mutation-positive NSCLC? The data too good to overlook. (7/18) (video)

How do patients with advanced NSCLC on daily steroids do on immune checkpoint inhibitors? (7/18) (video)

Local therapy for advanced NSCLC: revising outdated principles for selected patients (9/18) (video)

“Best treatment first”: implications for front-loading combinations in lung cancer (9/18) (video)

Impower133: is there finally a new standard of care for extensive stage SCLC? (11/18) (video)

Updated results on PACIFIC trial: should we revise who should receive consolidation immunotherapy after chemo/radiation? (11/18) (video)

Long-term management of patients doing well on immunotherapy for advanced NSCLC: insights from KEYNOTE-010 (11/18) (video)

Pembrolizumab for patients with advanced NSCLC and a performance status (PS) of 2: results of the PePS2 trial (11/18) (video)

The MYSTIC trial has failed on overall survival in advanced NSCLC: what does and doesn't this tell us? (12/18) (video)

The IMpower132 trial: does this change the advanced NSCLC landscape? (12/18) (video)

Overall survival benefit for local ablative therapy as consolidation for oligometastatic stage IV NSCLC: where does it fit in practice now? (12/18) (video)
 The IMpower130 trial of carbo/nab-paclitaxel +/- atezolizumab: does this positive trial change management? (12/18) (video)
 What does the CheckMate-331 trial of nivo vs. chemo for relapsed SCLC tell us? (12/18) (video)
 Top 5 most influential trial findings in lung cancer management in 2018 (12/18) (video)

West Wind Podcasts

Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (3/19) (audio)
 Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (3/19) (audio)
 Dr. David Gandara: Cultivating Careers, Shaping Clinical Cancer Research, & Integrating Blood-Based Testing (3/19) (audio)
 Dr. Joan Schiller: Changes in lung cancer management, leading a nonprofit, addressing stigma, & the rise of online patients (3/19) (audio)
 Dr. Matthew Gubens: Integration of Teleoncology into Clinical Practice, Mounting Data on Plasma NGS, & Preserving Work-Life Balance (3/19) (audio)
 Drs. Christine Hann & Stephen Liu: Moving the Needle in Small Cell Lung Cancer (3/19) (audio)
 Dr. Alex Drilon: Clinical Research and the Changing Practice of Managing Molecularly-Defined, Narrow Subgroups (3/19) (audio)
 Dr. Giorgio Scagliotti: Shaping the Transformation of Thoracic Oncology (3/19) (audio)
 Dr. Gil Morgan (Part 1): Social Media & Digital Education Cultivating a Global Oncology Community (4/19) (audio)
 Dr. Gil Morgan (Part 2): Overcoming Barriers in Cancer Care Delivery, Smoking Cessation, & Lung Cancer Screening Globally (4/19) (audio)
 Weighing the clinical significance of new clinical trial results with immunotherapy in stage III and IV NSCLC (4/19) (audio)
 Dr. Jed Gorden (Part 1): Rolling Out Chest CT Screening and Pulmonary Workups into the Real World Beyond Tertiary Care Centers (4/19) (audio)
 Dr. Jed Gorden (Part 2): Defining the Role of Interventional Pulmonology in a New Era of Lung Cancer Management (4/19) (audio)
 Dr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLC (4/19) (audio)
 Dr. Charu Aggarwal (Part 1): Growing Momentum for Plasma-Based NGS Testing in Advanced NSCLC (4/19) (audio)
 Dr. Charu Aggarwal (Part 2): Building a Career and Family Life Together, Overcoming Barriers (4/19) (audio)
 Dr. Bishal Gyawali (Part 1): Truly Global Perspective on Oncology Care, from Kathmandu to Canada (4/19) (audio)
 Dr. Bishal Gyawali (Part 2): The Cancer Ground-Shot, Enforcing Common Sense, and Stirring the Pot While Rethinking Dubious Standards in Cancer Care (5/19) (audio)
 Dr. Sanjay Mukhopadhyay (Pt. 1): Medical Education & Outreach in the Age of Social Media (5/19) (audio)
 Dr. Sanjay Mukhopadhyay (Pt. 2): Integrating Artificial Intelligence, Telemedicine, and Other New Technologies to Improve Pathology Globally (5/19) (audio)
 Dr. Greg Riely (Pt 1): Current Practice & Challenges in Execution of Genomic Testing in Lung Cancer Treatment (5/19) (audio)
 Dr. Greg Riely (Pt 2): Should local ablation therapy in oligometastatic or oligoprogressing cancer be incorporated into routine practice? (5/19) (audio)
 Dr. Mark Lewis (Pt. 1): The Fateful Path to a Medical Career and Self-Diagnosis (5/19) (audio)
 Dr. Mark Lewis (Pt. 2): Managing My Cancer Diagnosis, from Watchful Waiting to a Whipple Procedure (5/19) (audio)

Dr. Mark Lewis (Pt. 3): Raising a Family while Managing a Familial Cancer Syndrome (5/19) (audio)

Dr. Ross Camidge (Pt 1): Working at the Forefront of Developing New Targets and New Therapies (5/19) (audio)

Dr. Ross Camidge (Pt 2): NCCN Guidelines, New Research Initiatives, & Partnering with Patient Groups (6/19) (audio)

Dr. Heather Wakelee: Prioritizing Mentorship & Leadership in Thoracic Oncology (6/19) (audio)

Dr. Monty Pal: From an Early Commitment to Medicine Down the Path to ASCO and GU Oncology Leadership (6/19) (audio)

Dr. Lecia Sequist (Pt. 1): Combining Interests in Science and Practical Issues in Cancer Care (6/19) (audio)

Dr. Lecia Sequist (Pt. 2): Post-ASCO Debrief & Efforts with IASLC (6/19) (audio)

Dr. Chadi Nabhan (Pt 1): Reviewing the Path in a Medical Career from Clinic to the Business of Health Care (6/19) (audio)

Dr. Chadi Nabhan (Pt 2): Reflecting on Career Priorities, Struggling to Say No, & Defining a Place for Real World Evidence in Cancer Treatments (6/19) (audio)

Dr. William Dale (Pt 1): Developing a Focus on Supportive Care and Geriatric Oncology (6/19) (audio)

Dr. William Dale (Pt 2): Integrating Supportive Care with Aggressive Anti-Cancer Therapies (6/19) (audio)

Dr. Esther Choo (Pt 1): Medical Care & Social Policy in the ER (6/19) (audio)

Dr. Esther Choo (Pt 2): Gender Equity in Medicine, Social Media & Mass Media (7/19) (audio)

Dr. Puneeth Iyengar (Pt 1): The Appeal of Entering Radiation Oncology, & How the Field is Evolving (7/19) (audio)

Dr. Puneeth Iyengar (Pt 2): Open Questions and Controversies in Radiation Oncology Today (7/19) (audio)

Dr. Suzanne Dahlberg: A Statistician's Perspective on the Changing Landscape of Clinical Trials in Cancer (7/19) (audio)

Dr. Sandip Patel (Pt 1): The Importance of Language & Good Communication to Connect with Patients (7/19) (audio)

Dr. Sandip Patel (Pt 2): Advances and Impasses in Precision Medicine for Cancer (7/19) (audio)

Dr. Jack West on New Data Combining Radiation with Immunotherapy in Advanced NSCLC: A Brief Critical Review (7/19) (audio)

Dr. Gideon Blumenthal (Pt 1): The Journey into Working for the FDA on Cancer Treatment Regulation (7/19) (audio)

Dr. Gideon Blumenthal (Pt 2): Working to Balance Access, Efficacy, and Safety at the FDA (7/19) (audio)

Dr. Hossein Borghaei (Pt 1): On His Own at 16, Journey from Tehran to Philadelphia (7/19) (audio)

Dr. Hossein Borghaei (Pt 2): Reflecting on Progress & Future Directions in Immunotherapy (7/19) (audio)

Dr. Jerad Gardner (Pt 1): Pioneering How Physicians Use Social Media to Build Community & Educate (7/19) (audio)

Dr. Jerad Gardner (Pt 2): Facilitating New Research with Online Patient Groups, and the Future of Integrating AI in the Pathology Workflow (7/19) (audio)

Dr. Luis Raez: A Deep Commitment to Medical Education and Leadership (7/19) (audio)

Dr. Tim Gilligan (Pt 1): Developing a Focus on Genitourinary Oncology (8/19) (audio)

Dr. Tim Gilligan (Pt 2): Improving Oncologist-Patient Communication Skills (8/19) (audio)

Ishwaria & Vivek Subbiah (Part 1): Origin Story for a Great Oncology Power Couple (8/19) (audio)

Ishwaria & Vivek Subbiah (Part 2): Integrating Novel Treatments and Supportive Care in a Tertiary Care Referral Center (8/19) (audio)

Dr. Anne Tsao: The Path to Medicine, MD Anderson, & a Focus on Mesothelioma (8/19) (audio)

Dr. Gilberto Lopes (Pt 1): Medical Perspective From Working on Three Continents (8/19) (audio)

Dr. Gilberto Lopes (Pt 2): The Growing Momentum of Global Oncology (8/19) (audio)

Dr. David Palma (Pt 1): Radiation Oncologist, Triathlete, Bestselling Author (8/19) (audio)

Dr. David Palma (Pt 2): Controversies and Open Questions in Radiation Oncology (8/19) (audio)

Dr. Miriam (Mimi) Knoll (Pt. 1): Her Upbringing in an Unusually Medical Household (9/19) (audio)

Dr. Miriam (Mimi) Knoll (Pt. 2): Reaching a Broad Audience on Social & Mass Media (9/19) (audio)

Chris Draft & Tabitha Paccione (Pt 1): Facing a New Diagnosis of Lung Cancer (9/19) (audio)

Chris Draft & Tabitha Paccione (Pt 2): The Strength of a Lung Cancer Community, Live and Online (9/19) (audio)

Dr. Cathy Eng (Pt 1): Beloved GI Oncologist and Bad-Ass Kickboxer (9/19) (audio)

Dr. Cathy Eng (Pt 2): Controversies and Open Questions in GI Oncology (9/19) (audio)

Dr. Narjust Duma (Pt 1): From Venezuela and the Dominican Republic to Minnesota and Wisconsin (9/19) (audio)

Dr. Narjust Duma (Pt 2): Forging Connections among Latinas in Medicine, and among Women in Hematology & Oncology via Social Media (9/19) (audio)

Ivy Elkins & Jill Feldman (Pt 1): Finding Your Footing in the Face of a New Lung Cancer Diagnosis (9/19) (audio)

Ivy Elkins & Jill Feldman (Pt 2): Cancer Support and Education from Fellow Patients, Locally and Online (10/19) (audio)

Ivy Elkins & Jill Feldman (Pt 3): Patient Advocates Working with Physicians and Professional Societies (10/19) (audio)

Dr. Tony SK Mok: A Few Things You Probably Knew About Him, and a Bunch More You Didn't (10/19) (audio)

Dr. Yuman Fong (Pt 1): Balancing Professional and Personal Life Along the Path to a Career in Surgical Oncology (10/19) (audio)

Dr. Yuman Fong (Pt 2): Multidisciplinary Cancer Care, and Redefining the Role of Local Therapy in Metastatic Cancer (10/19) (audio)

Dr. Ben Solomon: A Journey from Sri Lanka to Zambia to Australia (10/19) (audio)

Dr. Reshma Jaggi (Pt 1): How a Government Major Who Worked in the White House Became Drawn into Medicine (10/19) (audio)

Dr. Reshma Jaggi (Pt 2): Identifying and Addressing Gender-Based Disparities in Medical Career Paths (10/19) (audio)

Dr. Benjamin Besse: National Collaboration Throughout France to Accelerate Precision Medicine Research in Cancer Care (10/19) (audio)

Dr. Jean-Charles (Pt 1): A Personal and Career Path Shaped by the Harrowing Effects of Illness (11/19) (audio)

Dr. Jean-Charles (Pt 2): Transitioning from Life in Paris to the US and from Academia to Industry (11/19) (audio)

Dr. Brendon Stiles (Pt 1): Childhood on the Farm, the Intellectual and Personal Call to Fight Lung Cancer, and Engaging in MedTwitter "Fight Club" (11/19) (audio)

Dr. Brendon Stiles (Pt 2): Evolving Standards and Open Controversies in Thoracic Surgery for Lung Cancer (11/19) (audio)

Dr. Tatiana Prowell (Pt 1): The Serendipitous Path to Career, Family, and Selecting What to Say No To (11/19) (audio)

Dr. Tatiana Prowell (Pt 2): The Appeal of a Focus on Breast Cancer & Working at FDA Alongside Clinical Practice and Research (11/19) (audio)

Dr. Tatiana Prowell (Pt 3): Shaping Oncology Research & Education through the Vail Workshop, ASCO, Mentoring, and Social Media (11/19) (audio)

Dr. Taofeek Owonikoko (Pt 1): Growing Up & Training in Nigeria, then Germany, Before Heading to US (12/19) (audio)

Dr. Taofeek Owonikoko (Pt 2): Focusing on Thoracic Oncology & Building a Career at Emory (12/19) (audio)

Dr. Fumiko Chino (Pt 1): The Challenges of Serving as a Caregiver to a Young Spouse with Cancer (12/19) (audio)

Dr. Fumiko Chino (Pt 2): Studying and Raising Awareness of Financial Toxicity in Cancer Care (12/19) (audio)

Dr. Sanjay Popat (Pt 1): The Path to Leadership in Thoracic Oncology in the UK (12/19) (audio)

Dr. Sanjay Popat (Pt 2): Precision Medicine and Therapy in a Nationalized, Regulated System (12/19) (audio)

Dr. Stacy Gray (Pt 1): Career Path and an Early Interest in Direct to Consumer Genetic Testing (12/19) (audio)

Dr. Stacy Gray (Pt 2): Overcoming Hurdles in Broader Use of Molecular Testing in Oncology (1/20) (audio)

Dr. Nina Niu Sanford (Pt 1): The Cultural and Educational Journey from Beijing to Boston to Dallas (1/20) (audio)

Dr. Nina Niu Sanford (Pt 2): Integrating Parenthood with the Transition to Young Attending Building a Clinical and Research Focus (1/20) (audio)

Dr. Petros Grivas: The Journey from Greece to the US, and the Difficult Question of When to Move (1/20) (audio)

Dr. Marina Garassino: Navigating a Path to Leadership in Thoracic Oncology Research and Education in Italy (2/20) (audio)

Dr. Brandon Mahal: Rising from a Youth of Gang Culture and Dodging Bullets to Harvard Medical School and Beyond (2/20) (audio)

Dr. Alfredo Addeo: Lessons Learned from Practicing Oncology in Multiple European Countries (2/20) (audio)

Dr. Jack West: Exploring and Explaining the Shortcomings in Molecular Testing and Execution of Targeted Therapy (2/20) (audio)

Dr. Jarushka Naidoo: South African TV Personality, Dublin Medical Trainee, Shakespearean Stage Actor, and Johns Hopkins Immunotherapy Toxicity Expert (3/20) (audio)

Drs. Jack West and Charu Aggarwal: New Data on Liquid Biopsies, Tumor Mutational Burden, and Choosing Optimal Systemic Therapy Today (3/20) (audio)

Dr. Nate Pennell: Social Media, Virtual Learning, and Medical Mega-Conferences (3/20) (audio)

Dr. Christian Rolfo: Living and Working in 3 Continents, Now Working on Early Therapeutics, Liquid Biopsies, & Global Oncology (3/20) (audio)

Cancer Care in a Pandemic: Challenging the Status Quo (3/20) (audio)

Sarah Mojarad: Social Media Training in Science and Medicine (4/20) (audio)

Beyond the Journal Podcasts, Co-hosted with Dr. Charu Aggarwal (video and audio)

Dr. Mark Lewis, on Authenticity and a Personal Voice in Social Media (11/20)

Dr. Gil Morgan, on OncoAlert and Developing a Global Online Cancer Community (11/20)

Dr. Sanjay Popat, Debating with Us Where the Dust has Settled with Adjuvant Osimertinib After the ADAURA Trial (12/20)

Dr. Jamie Von Roenn and Christopher Merlan, on ASCO's Virtual Annual Meeting and the Future of Digital Education (12/20)

Dr. Nora Disis, on the Evolution of Academic Publishing and New Patterns of Sharing Information (12/20)

Dr. Don Dizon on Social Media and Equity in Oncology (1/21)

Dr. Julie Gralow, on Integrating Advocacy and Global Oncology with Cancer Care Leadership (1/21)

Dr. Toni Choueiri, on the Value of Social Media, Remote Mentoring, and Balancing Professional Focus with Personal Convictions (2/21)

Drs. Susan Love and Stephanie Graff on Advocacy, Patient Education and Outreach for Breast Cancer Research (2/21)

Dr. Vincent Rajkumar, on the Transition of Academic Publishing to Digital Platforms, the Goals of Physicians on Social Media, and the Successful Use of Telemedicine at Mayo Clinic (3/21)

Drs. Jerad Gardner & Sanjay Mukhopadhyay, on Strengthening a Global Community Around Digital Education (3/21)

Drs. David Palma and Puneeth Iyengar, on Defining the Oligometastatic State and Refining the Role of Radiation Therapy in Metastatic Cancer (4/21)

Dr. Samyukta Mullangi, on Paths to Improving on the Current Dysfunctional System of State-Based Medical Licensing to Work with Current Practice Needs (4/21)

Dr. Steve Vogl, on Keeping Focused on the Endpoints that Truly Matter in Cancer Care (5/21)

Dr. Petros Grivas, on Adapting to Digital Education and Remote Mentorship Opportunities (5/21)

Dr. Chadi Nabhan, on the Transition Between Academia, and the Appeal of Different Social Media Platforms to Discuss Timely Issues in Medicine (6/21)

Dr. Pamela Kunz, on Professional Advancement as a Woman, & Changing Cultures that Enable Sexual Harassment (6/21)

Dr. Vince Miller, on the Weighty Decision of a Move to Industry, the Barriers to Molecular Marker Testing, and Disrupting the Pricing of Cancer Therapies

Dr. Shikha Jain, on the Women in Medicine Summit and Post-Pandemic Medical Education & Practice (7/21)

Dr. Larry Shulman, on Telemedicine at Home and Abroad, Physician Burnout, and Global Oncology (7/21)

Dr. Matthew Katz, on Communicating Effectively to the Lay Public, and Social Media Focused on Bringing it Back to the Patient (8/21)

Dr. Patrick Forde, on the Practical Benefits and Clinical Promise of Neoadjuvant Therapy and Pathology Assessment in Early NSCLC (8/21)

Dr. Mikkael Sekeres, on the Adventures of a Midcareer Move and the Art of the Clinical Narrative (9/21)

Dr. Aaron Goodman, on Novel Platforms for Medical Education & Reaching a Global Community via Twitter Polls (9/21)

Dr. Jyoti Patel on Career Transitions and Cancer Education (10/21)

Dr. MJ Markham, on Addressing Gender Bias, Educating on COVID, and Social Media for Physicians and Journals (10/21)

Dr. Leora Horn, on New Challenges in Industry After Academia, and the Effort to Balance Career and Family (11/21)

Dr. Erika Hamilton, on How COVID-19 has Impacted Clinical Trial Conduct, Telemedicine, and Our Social Media Discourse (11/21)

Leading Thoughts: Lung Cancer (OBR Oncology podcast; co-hosts Charu Aggarwal, MD & Devika Das, MD)

Early impressions of IMpower010: what might this mean for immunotherapy in early-stage non-small cell lung cancer? (4/21)

What is the role of ipi/nivo-based treatment in advanced non-small cell lung cancer (4/21)

What does it mean when a new agent beats an obsolete control arm? (5/21)

Lurbinectedin and ATLANTIS: What do the clinical data tell us about how to treat relapsed small cell lung cancer? (5/21)

Is neoadjuvant immunotherapy ready for prime time in early stage non-small cell lung cancer (NSCLC)? (5/21)

Interpreting Keynote-024 in metastatic NSCLC (6/21)

IMpower010 and adjuvant atezolizumab at ASCO 2021 (6/21)

Newly approved sotorasib: dissecting the clinical data, and how to use it in practice (7/21)

Treating patients with EGFR exon 20 insertion mutations (7/21)

Disparities in biomarker testing in NSCLC (7/21)

PACIFIC's 5-year follow-up at ASCO '21 (8/21)

Optimal radiation therapy for limited stage SCLC (8/21)

Emerging data on NSCLC with brain metastases (9/21)

I-O in NSCLC after targeted therapy (9/21)

HER2-directed therapy in NSLCC (11/21)

SBRT in oligoprogressive NSCLC (11/21)

Best of NSCLC 2021 (12/21)

Adjuvant pembrolizumab in NSCLC (2/22)

Sintilimab's ODAC rejection and pricing (3/22)

Groundhog Day: GEMSTONE-302 is published in Lancet Oncology, but so what? (3/22)

Neoadjuvant nivolumab for NSCLC (3/22)

Toripalimab: Another PD-1 inhibitor for NSCLC? (5/13)

Adjuvant chemo in NSCLC: Lessons from the real world (6/22)

Concurrent blood and tissue NGS testing in NSCLC (7/22)

Chemoimmunotherapy v. immunotherapy in NSCLC (8/22)

Should LUNG-MAP S1800A change care? (9/22)
 Lung cancer immunotherapy in patient subsets (9/22)
 Adding immunotherapy to sotorasib: is it safe? (10/22)
 CodeBreak200: just good enough? (11/22)
 Adjuvant osimertinib benefit fades over time (11/22)
 Who should receive adjuvant atezolizumab (12/22)
 Top highlights of 2022 in lung cancer (12/22)
 Treating NSCLC with uncommon EGFR mutations (2/23)
 Adjuvant pembrolizumab: clinically valuable? (3/23)
 Is anti-TIGIT therapy in NSCLC worth it? (4/23)
 “Wary of Immunotherapy” in NSCLC? (4/23)
 Perioperative immunotherapy concerns in NSCLC (5/23)
 Who should undergo resection in early NSCLC? (5/23)
 Is immunotherapy after NSCLC progression futile? (7/23)

Other media (as featured expert or writer)

A patient with bronchioloalveolar carcinoma treated with single-agent gefitinib, Case Studies in Lung Cancer (CME), 3/04
 Lung Cancer Think Tank, Research to Practice, 5/05
 Discovery Channel CME: Individual Therapy for Non-Small Cell Lung Cancer, Discovery Channel, 8/2010.
 Profiles in oncology social media: Howard (Jack) West, MD, @JackWestMD. Oncology Times. 36: 36-37, 3/14.
 RxDM StoryCast: Dr. Jack West, Oncologist, CancerGRACE. Rx Digital Marketing podcast. 1/17.
 Osimertinib granted full approval for NSCLC, Oncology Times 39: 34, 5/17.
 Biotech strategy blog: audio podcast, The PD-L1 gorilla is back, 4/18.
 Next-generation sequencing, with Jack West. Outspoken Oncology podcast, 4/19.
 Patients, Caregivers, and Clinicians in Partnership. Lung Cancer Voices (Lung Cancer Canada Podcast), 6/19.
 West H. Mind the Gap: ASCO 2019 highlights new molecular targets in advanced NSCLC, but we're failing to execute on the best care available now. Heme/Onc Today, 7/19.
 Can plasma tumor mutational burden measures inform lung cancer therapy selection? Cancer Therapy Advisor, 5/20.
 Non-small cell lung cancer: how to choose the best therapy and reviewing the first virtual ASCO. Blood & Cancer/MD Edge Podcast, 6/20.
 Heme/Onc Medical Oncology Twitter Journal Club, guest expert; SELECT and ADAURA trials. 6/20.
 Debating the ADAURA Trial with Jack West and Nathan Pennell. Outspoken Oncology Podcast, 7/20.
 Optimizing Next Generation Sequencing for NSCLC, ReachMD Interview, 12/21.
 Beyond Adjuvant Chemotherapy: Precision Oncology in Early Stage NSCLC, ASCO Podcast, 12/21
 Lung Cancer Considered: ASCO 2022 Highlights, with Jack West and Catherine Shu, 6/22
 Plenary Session with Vinay Prasad: H. Jack West on Lung Cancer, Podcasting, Telehealth, PACIFIC, ADAURA, CM817, and KN189, 6/22
 Oncology Brothers Podcast: Lung Abstract Highlights, #ASCO22, with Jack West, 6/22
 When Practice Evolves Faster Than Data in Early Stage NSCLC, ASCO Post, Eric Singhi & H. Jack West
 Looking Back at Telemedicine During the COVID-19 Era: Lessons Learned and Disparities Identified (featured presenter, extensively quoted), ASCO Post, 6/22.
 Real-world DFS as predictor of OS in resected early-stage non-small cell lung cancer (video), VJ Oncology, 8/22.
 The Fellow on Call podcast: NSCLC Capstone with Dr. Jack West (Parts I and II), 10/22
 Rethinking the Treatment Approach to Resectable Non-Small Cell Lung Cancer: Do New Approvals Always Translate to Clinical Value? ASCO Daily News, Eric Singhi & H. Jack West, 4/2023
 Jack West and Julia Rotow discuss ADAURA trial takeaways (Medscape video), 6/2023
 For NSCLC, neoadjuvant, adjuvant, or both? (Medscape video), 6/2023
 “Aspirationally Resectable”? Neoadjuvant Tx Evolves in NSCLC (Medscape video), 9/2023

